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Abstract
In treatment of central nervous system (CNS) diseases, the blood-brain barrier (BBB) is the
main obstacle preventing drug molecule penetration from the bloodstream into the brain. In
this thesis dendronized streptavidin (DSA) and fluorescent nanodiamonds (fNDs)
encapsulated by a human serum albumin (HSA)-based biopolymer (dcHSA-fNDs) are
presented as promising platforms for treatment of neurological disorders via crossing an intact
BBB. DSA provides a flexible bio-click system composed of an adapter of tetrameric
streptavidin linked to biotinylated PAMAM dendrimers, holding the potential to apply
synergistically intrinsic therapeutic function of PAMAM dendrimers combined with any
biotinylated drug activity on one platform. dcHSA-fNDs represent a very peculiar
nanotheranostics tool characterized by the unique optical and magnetic properties of fNDs.
Moreover, the HSA-based coating provides colloidal stability and improved functionalization
capability. Thus, dcHSA-fNDs exhibit the potential of real time monitoring of drug delivery.
In this thesis it is successfully demonstrated that both nanocompounds (1) are able to
penetrate neurovascular unit (NVU) cells as shown by confocal imaging, immunocytochemical
and biochemical analysis; (2) are transported from one side to the other of in vitro BBB models
employing porcine and murine mono-cultures or murine triple co-cultures and, (3) the
transport occurs via intracellular trafficking without induction of autophagy demonstrated by
confocal analysis of colocalization with specific intracellular markers; (4) do not affect NVU
cells viability and BBB integrity according to transendothelial electrical resistance monitoring,
(5) are able to reach the brain and target NVU cells in vivo after intravenous injection as
observable from screening of brain slices combined with immunohistochemistry. Specifically,
DSA undergo lysosomal escape preserving cargo-carrier intracellular integrity and do not
induce BBB disruption also in vivo validated by Evans Blue assay; dcHSA-fNDs show direct cell-
cell migration in NVU cells moving along tunneling nanotubes; the mechanism occurs also
among different cell types as observable combining live cell imaging and immunocytochemical
analysis. For fNDs, this doctoral thesis provides for the first time reliable data on in vivo brain
delivery and mechanisms of transport across the BBB.
 In summary, in this thesis two nanoplatforms targeting the brain using highly biocompatible
non-invasive strategies to develop various therapeutic approaches are investigated in detail.
Abbreviations
AD Alzheimer disease
BAF Bafilomycin A1
BBB Blood-Brain Barrier
bEnd.3 Murine brain endothelial cell lines
cAMP Cyclic adenosine monophosphate
CcL Capacitance of the cell layer
CD105 Endoglin
CED Convection enhanced diffusion
CNS Central nervous system
CS Coverslips
CTR Control
CTX Subunit B of cholera toxin
DALYs Disability-adjusted life years
DAPI 4',6-diamidino-2-phenylindole
dcHSA-fNDs Fluorescent nanodiamonds encapsulated by human serum albumin-based
biopolymer
DIV Day in vitro
DMEM Dulbecco´s modified Eagle medium
DSA Dendronized streptavidin
EB Evans blue
EBM-2 Endothelial growth basal medium
ECIS Electrical cell impedance sensing
EDTA Ethylenediaminetetraacetic acid
EE Early endosomes
EEA Early endosome antigen
FCS Fetal calf serum
FD4 FITC-Dextran 4
fNDs Fluorescent nanodiamonds
FUS Focused ultrasound
GFAP Glial fibrillary acidic protein
HBSS Hank´s balanced salt solution
HD Huntington disease
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic Acid
HS Horse serum
HSA Human serum albumin
ICV Intracerebroventricular infusion
LAMP-1 Lysosomal-associated membrane protein 1
LC3 Microtubule-associated protein 1A/1B-light chain 3
LE Late endosomes
MEM Minimum essential medium
NDs Nanodiamonds
NeuN Neuronal nuclear antigen
NPs Nanoparticles
NV Nitrogen vacancy
NVU Neurovascular unit
PAMAM Poly-amidoamine
Papp Apparent permeability
PBECs Porcine brain endothelial cells
PBS Phosphate buffered saline
pCPT-cAMP 8-(4-Chlorophenylthio)adenosine 3ʹ,5ʹ-cyclic monophosphate sodium salt
PD Parkinson´s disease
PVDF Polyvinylidene fluoride
SA Streptavidin
SDS Sodium dodecyl sulfate
TBI Traumatic brain injury
TEER Transendothelial electrical resistance
TF Transferrin
TfR Transferrin-receptor
TJs Tight junctions
TNTs Tunneling nanotubes
TUNEL Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling
VAMP3 Vesicle-associated membrane protein 3
v-SNARE Vesicle soluble N-ethylmaleimide-sensitive-factor attachment receptor
WHO World health organization
ZO1 Zona occludens 1
Table of contents
1. Introduction ....................................................................................................................... 1
1.1 Neurological diseases: a challenge for public health ....................................................... 1
1.2 The BBB: a challenge for neurological disease treatments  ............................................. 3
        1.2.1 Current state of research: strategies to cross the BBB and their limits  ................... 6
  1.3 Nanotechnology: a promising approach for development of new therapeutic strategies
  ....................................................................................................................................... 8
  1.4 From protein-based nanomaterials to dendronized streptavidin bioconjugates .............. 9
         1.4.1 Streptavidin: a flexible scaffold for biomaterials assembly  .................................. 12
1.5 From nanotheranostics to fluorescent nanodiamonds  ................................................. 12
         1.5.1 Nanodiamonds as suitable nanotheranostics agents  ........................................... 13
         1.5.2 Albumin, a carrier system..................................................................................... 15
2. Aim of the study ...................................................................................................... 17
3. Material and Methods  ............................................................................................. 18
3.1 In vitro assays for evaluation of BBB crossing capability of DSA and dcHSA-fNDs  ......... 18
         3.1.1 Culturing of bEnd.3 cells …………………………………………………………………………………….20
         3.1.2 Isolation of Porcine Brain Endothelial Cells (PBECs)  ............................................. 20
         3.1.3 Isolation of primary murine astrocytes  ................................................................ 23
3.1.4 Isolation of primary murine neurons  ................................................................... 23
3.1.5 Preparation of triple co-culture BBB model  ......................................................... 24
         3.1.6 Evaluation of NPs transport across BBB  ............................................................... 25
         3.1.7 Measurement of transendothelial electrical resistance  ....................................... 26
         3.1.8 Analysis of NPs cell uptake  .................................................................................. 28
         3.1.9 Evaluation of cell vitality  ..................................................................................... 28
         3.1.10 Preparation of cell lysates  ................................................................................. 29
         3.1.11 Concentration of proteins in medium samples  .................................................. 29
         3.1.12 Protein detection by Western Blot ..................................................................... 30
         3.1.13 Analysis of autophagy induction  ........................................................................ 30
         3.1.14 Analysis of DSA short-term lysosomal degradation  ............................................ 30
         3.1.15 Characterization of dcHSA-fNDs transport along TNTs ........................................31
   3.2 In vivo assays for evaluation of BBB crossing capability and biodistributional studies of
 DSA and dcHSA-fNDs .................................................................................................... 31
         3.2.1 Intravenous injection of NPs in mice  ................................................................... 31
         3.2.2 Tissue harvesting for NPs uptake analysis by confocal imaging  ............................ 32
         3.2.3 Preparation of brain lysates and quantification of DSA in vivo brain uptake.........32
         3.2.4 Evaluation of BBB integrity by Evans Blue (EB) extravasation assay  ..................... 33
3.3 Immunocytochemical and histochemical analysis  ........................................................ 34
3.4 Image processing and analysis  ..................................................................................... 36
   3.5 Statistic data analysis  .................................................................................................. 36
4. Results  ................................................................................................................... 37
   4.1 Dendronized Streptavidin for brain drug delivery via crossing an intact BBB  ............... 37
         4.1.1 DSA are taken up by brain endothelial cells in vitro  ............................................. 37
         4.1.2 DSA are efficiently transported across BBB in vitro .............................................. 40
         4.1.3 DSA follow a transcytotic pathway without short term intracellular
                   degradation and involvement of autophagic mechanisms  ................................... 43
         4.1.4 DSA do not affect bEnd.3 cell vitality and BBB integrity  ....................................... 49
         4.1.5 DSA uptake in astrocytes and neurons occurs without cytotoxic effects  .............. 51
         4.1.6 DSA are transported to the brain and taken up by NVU cells in vivo  .................... 53
         4.1.7 DSA reach also peripheral organs in vivo after intravenous injection ................... 57
         4.1.8 DSA do not affect BBB integrity in vivo  ................................................................ 58
    4.2 Fluorescent nanodiamonds as nanotheranostics platform for brain drug delivery via
 crossing an intact BBB  ................................................................................................ 60
         4.2.1 dcHSA-fNDs are taken up by brain endothelial cells in vitro  ................................ 60
         4.2.2 dcHSA-fNDs are transported across BBB in vitro in a size-independent manner ... 63
 4.2.3 dcHSA-fNDs transport employs transcytosis involving endosomal localization  .... 64
         4.2.4 dcHSA-fNDs are taken up by astrocytes and neurons in vitro  .............................. 67
         4.2.5 dcHSA-fNDs show direct cell-cell migration mediated by actin bridges ………………68
         4.2.6 dcHSA-fNDs do not affect cell vitality and BBB integrity in vitro  .......................... 72
         4.2.7 dcHSA-fNDs cross the BBB and reach the brain after intravenous injection in
                    mice ……………………………………………………………………………………………………………….. 73
5. Discussion ............................................................................................................... 76
5.1 Dendronized Streptavidin represents a promising nanoplatform for brain drug
 delivery  ........................................................................................................................ 76
   5.2 Fluorescent Nanodiamonds might contribute to the improvement of nanotheranostics
 approaches for neurological diseases treatments  ........................................................ 86
6.      Conclusions and future prospects  ......................................................................... 91
7.      References ……………………………………………………………………………………………………………..94
11. Introduction
1.1 Neurological diseases: a challenge for public health.
In the 2006 the World Health Organization (WHO) signed a document presenting in deep
details the Global Burden of Disease for neurological disorders from the projected estimates
for 2005, 2015 and 2030 (WHO 2006). The emerging scenario showed a dramatic situation
with a final clear message: “unless immediate action is taken globally, the neurological burden
is expected to become an even more serious and unmanageable threat to public health”.
Neurological disorders are estimated to affect as many as a billion people worldwide, no
population group is immune, and the annual economic cost amounted to € 139 billion in 2004,
only partially including direct non-medical costs, indirect costs and omitted intangible costs.
In addition, the stigma often associated to neurological disorders is reflected in a strong self-
destructive behavior to refuse treatments, hoping to avoid the negative social consequences
of diagnosis and leading to social exclusion and discrimination. As shown in Figure 1,
neurological disorders constituted 6.3 % of the global burden of disease (expressed in
disability-adjusted life years (DALYs) as measurement of the total number of years lost
because of death or disabilities), that, if compared to the data for HIV/AIDS and malignant
neoplasm (slightly over 5% each), highlight their high impact on public health. Therefore, due
to the social and economic relevance of neurological diseases, the WHO´s report evidences
the need of immediate and effective therapeutic treatments.
Figure 1.  Percentage of total DALYs (total number of healthy-life years lost
because of death or disabilities) for selected diseases and neurological disorders.
The data in the graph represent the DALYs as measurement of the gap between
current health status and an ideal health situation where the entire population
lives to an advanced age, free of disease and disability. (modified from WHO, 2006)
2On the basis of this described global situation, the work of many researchers has been focused
on the identification of the underlying mechanisms of central nervous system (CNS)
pathophysiology. Therefore, during the past years, the scientific community has made big
progresses to improve the knowledge on neurological disorders.
Among the many findings, some of the most important ones are as follows:
· Protein misfolding and following self-association and deposition of aggregated
proteins is observable in brain tissues of patients with neurodegenerative
disorders. For example, the aggregation of protein tau (a microtubule-associated
protein), of a 42-amino-acid form of β-amyloid or of α-synuclein leads to the
formation of neurofibrillary tangles or Lewie´s bodies that characterize
Alzheimer´s disease (AD), Huntington´s disease (HD), Parkinson´s disease (PD) and
other neurological disorders (LaFerla, Green and Oddo 2007, Reiman 2016,
Goedert 2001, Peelaerts and Baekelandt 2016).
· Immune activation and neuroinflammation represent a common link between
neurological diseases. Such activation can trigger neurotoxic responses leading to
progressive degeneration contributing to tissue damage. However, these
mechanisms also play important role in resolving inflammation and mediating
neuroprotection and repair (Amor et al. 2010, Fakhoury 2015).
· Mitochondrial dysfunction and oxidative stress are also important contributors to
the pathophysiology associated to most of the neurological disorders. In fact,
neuronal tissue is extremely sensitive to reactive oxygen species. Imbalance in pro-
oxidant versus anti-oxidant homeostasis in CNS shows a strong toxicity, as found
in AD, PD, HD and amyotrophic lateral sclerosis (Burté et al. 2015, Cherra and Chu
2008).
· Genetic mutations also trigger the onset of neurological diseases. For example,
protein aggregation associated to several neurodegenerative disorders is often
related to mutations in the gene encoding for that protein. Additionally, in the last
years, some studies showed that de novo mutations in genes regulating autophagy
cause static encephalopathy of childhood with neurodegeneration in adulthood.
Some other findings also suggest that somatic, perhaps brain-only, mosaic
3mutations may be important for other neurodevelopmental diseases (Poduri et al.
2013, Simonato et al. 2013).
The just described mechanisms are some of the much knowledge achieved in neurological
disease research. Thus, all these scientific achievements are constantly providing possible
therapeutic targets (Giacomelli, Daniele and Martini 2017, Colangelo, Alberghina and Papa
2014, Simonato et al. 2013, Harris and Rubinsztein 2011). Unfortunately, adequate treatments
for neurological disorders are still an unmet medical need, not only because of lack of possible
drugs, but also because systemically administered therapeutics are often ineffective due to a
well know biological obstacle: the blood-brain barrier (BBB).
1.2 The BBB: a challenge for neurological disease treatments
According to the actual knowledge, the BBB exists primarily as a selective diffusion barrier at
the level of the cerebral microvascular endothelium, characterized by the presence of tight
cell-cell junctions and a lack of fenestrations. The first interface from bloodstream is the cell
monolayer of brain capillary endothelial cells, which are in direct contact with pericytes and a
conjoint basal lamina. Astrocyte endfeets cover the capillary surface and represent the
connection to neurons (Daneman and Prat 2015, Ballabh, Braun and Nedergaard 2004). In
summary the BBB consists of brain capillary endothelial cells, pericytes, astrocytes and
neurons all referred to as the neurovascular unit (NVU) (Hawkins and Davis 2005) (Figure 2).
4Figure 2.  Components of the blood-brain barrier. Schematic representation of
BBB with immunocytochemistry staining of the main cell types involved (brain
endothelial cells stained with zona occludens-1, astrocytes stained with glial
fibrillary acidic protein and neurons stained with β-III-tubulin).
Anatomically, the difference between endothelial cells of the BBB and those in the periphery
lies in increased mitochondrial content, lack of fenestrations, minimal pinocytotic activity, and
presence of tight junctions (TJ). It is the presence of TJ that confers low paracellular
permeability and high electrical resistance. TJ functions as a “zipper” that affects separation
of the apical and basolateral cell membranes, enabling asymmetric distribution of membrane
constituents (Engelhardt, Patkar and Ogunshola 2014).
About pericytes at the actual state of art their contribution at BBB site is less characterized
compared to astrocytes. However, they are involved in the regulation of the blood flow and
to stabilize the formation of capillary-like structures as observed in co-culture experiments
(Ballabh et al. 2004, Engelhardt et al. 2014). Indeed, in some pathological conditions such as
traumatic brain injury (TBI), they migrate away from the capillary (Dore-Duffy et al. 2000). This
observation shows a possible relation between lost of pericytes at the BBB site and increase
of BBB permeability, typical benchmark of a pathological condition.
5Astrocytes are a critical cell type in the development and maintenance of BBB secreting
important molecules involved in the regulation of interactions between BBB components,
production of antioxidative agents, growth factors and neurotrophins important for brain cell
survival during neurodegenerative processes. Additionally, they represent the important
intermediates between blood and neurons regulating the neuronal trophic support (Abbott
2014, Engelhardt et al. 2014, Ballabh et al. 2004).
Whether neurons are critical in the development of BBB function has not yet been clearly
demonstrated, but it is apparent that, as feedback response, they can regulate some aspect
of BBB function. For example, it has been observed in AD a significant loss of cholinergic
innervation of cortical microvessels, which may lead to impaired cerebrovascular function
(Hawkins and Davis 2005).
All these cell types participate together to the proper function of the BBB. Indeed, the BBB is
a multicellular interface separating bloodstream and brain parenchyma, fulfilling the
important task of maintaining the sensitive homeostasis of the neuronal network. For optimal
activity, the CNS needs a perfectly regulated environment with characteristics far different
from those in the rest of the organism. The BBB isolates the brain and the spinal cord from
fluctuations in nutrients, hormones, metabolites and other blood constituents. It also protects
this tissue from the influence of endo- and exogenous compounds circulating in the blood.
Neuronal transmission is secured from the highly precise control of the microenvironment
regulated by the BBB. Additionally, the BBB participates to the protection from abrupt changes
in blood biochemistry after meals, physical exercises or pathological conditions. It is also
responsible of the constitutions of two well divided neurotransmitters pools: the one of the
central system and the one of the peripheral system (Bernacki et al. 2008).
Taken together, all these information provide an overview of the fundamental and remarkable
role of the BBB. Unfortunately, the BBB remains also a great challenge to struggle with for
scientists who work on neurological disease treatments. It represents, in fact, a “guardian”
that regulates access of drugs to the CNS under both physiological and pathological
circumstances.
After intravenous injection, only some lipophilic molecules can reach the brain parenchyma in
concentrations that are high enough to induce a therapeutic effect, and 98 % of neuroactive
6drugs, like all the products of biotechnology (e.g., monoclonal antibodies, recombinant
proteins or gene therapeutics) cannot cross the BBB (Pardridge 2007). Many of the
neurological disorders could be treated with drugs, enzymes or genes already discovered.
However, these molecules cannot enter into brain drug development because no BBB
solutions have been found by industry (Pardridge 2005).
1.2.1 Current state of research: strategies to cross the BBB and their limits
Currently, therapeutics can be delivered to the CNS via several ways. Either the drug
can circumvent the BBB after systemic administration or it has to be applied by
invasive methods. Possible approaches are, for example:
· Transcranial brain drug delivery using three neurosurgical-based delivery ways:
intracerebral implantation, intracerebroventricular infusion (ICV), convection
enhanced diffusion (CED). The limiting step for intracerebral and ICV relies on the
diffusion of a drug from the application site into brain tissue. Thus, we have to
consider that the concentration of a small molecule is decreased by 90 % at a
distance of only 0.5 mm from the intracerebral implantation site in rat brain. This
explains the inefficacy of these methods. Instead, CED consists of fluid
convection within the brain, established by maintaining a pressure gradient
during interstitial infusion. However, it is important to sign out that the brain is
not designed for a significant intraparenchymal volume flow (Pardridge 2005).
· Opening of the tight junctions via osmotic BBB disruption or ultrasound. The
osmotic disruption is also considered a surgical approach since it envisages the
use of anesthesia and a catheter. Furthermore, it is carried out in surgery room.
These approaches are based on the concept of tight junctions physical disruption
by shrinkage of CNS endothelial cells. Thus, hyperosmolar solutions can be used
to transiently breach the BBB. Instead, focused ultrasound (FUS) provides the
advantage of a selective and regional permeability increase resulting in
enhanced local delivery within the brain. Additionally, incorporation of
intravenously administered lipid-encapsed perfluorocarbon gas microbubbles
lowers the frequency threshold for BBB disruption, thereby allowing for much
7lower and safer frequencies to be used (Bellavance, Blanchette and Fortin 2008,
Etame et al. 2012).
Current techniques described above present all an unassailable limiting step: they
are invasive and involve a high risk of severe side effects. Indeed, the strategies
involving BBB disruption for brain drug delivery includes the risk of treatment-
induced seizures , temporary altered level of consciounsness and brain herniation
that are even related to some mortality events (Kamphorst, de Boer and Gaillard
2002). CED leads to diffuse white matter astrogliosis observable in autopsy of
primate brains as highlighted in a study of Ai and colleagues (Ai et al. 2003). On the
other hand, ultrasound-based approaches need further investigation to prove their
safety since there is a possible risk of tissue damage due to ultrasonic exposure
(Meairs and Alonso 2007). The just described considerations reporting a consistent
number of evidences for the lack of complete safety related to the actual therapies
raise obvious concerns about their long-term effects in humans. Additionally, the
limiting factor of the need of paramedical personnel and surgery rooms for the
above described treatments should not be underestimated. The possibility of
having a drug which could be systemically administered would provide the optimal
therapeutic condition, which, is still missing.
The only situations that do not only relay on the opening of the BBB for therapy are
the rare cases where, the pathological mechanisms by themselves, affecting BBB
integrity, might offer the possibility to access the brain. This is for example the case
for TBI (Kwon et al. 2016) or cancer (Caraglia et al. 2012) due to creation of
pathological fenestration in the brain microvessels. Still, also in these cases, an
enhanced delivery would be beneficial.
The goal of this doctoral study has been grounded to the need of finding a new
therapeutic approach for the unsolved problem of BBB drug crossing and
therapeutic molecule brain penetration. Therefore, my PhD research was based on
the following robust scientific statements. In humans, approximately 400 miles of
capillaries perfuse the brain, and the surface area of the brain microvascular
endothelium is around 20 m2. The density of the microvasculature in the brain is so
intricate that no neuron or glial cell is more than 20 µm away from its own
8microvessel (Urayama and Banks 2005). Furthermore, the trophic support of the
whole brain is guaranteed by the fact that every neuron has virtually its own
connection to a microvessel (Begley and Brightman 2003). Consequently, based on
these statements, the idea of delivering drugs via the NVU interface is one of the
most promising strategies to target the whole brain efficiently (Banks 2016).
1.3 Nanotechnology: a promising approach for development of new therapeutic
strategies
Nowadays, the increasing number of reports on designing compounds in the nanometer scale
may lead to the development of novel strategies for non-invasive therapy of neurological
diseases. Nanoparticles (NPs) are defined as particulate dispersions or solid particles with a
size usually in the range of 10-1000 nm. A possible drug can be dissolved, entrapped,
encapsulated or attached to a NP matrix (Singh and Lillard 2009). The potential of NPs as
delivery system is grounded to the following characteristics:
· The possibility of easy manipulation of particle size and surface to achieve both passive
(bearing no affinity ligands; directly related to inherent NPs biophysicochemical properties)
and active (incorporation of affinity ligands with specificity for diseased tissues and cells)
drug targeting after systemic administration (Kamaly et al. 2012).
· The ability to potentially control and sustain release of the drug during the transport and
at the site of localization and subsequent clearance of the drug so as to achieve increase in
drug therapeutic efficacy and reduction in side effects (Bamrungsap et al. 2012).
· Optimal modification of the surface to improve and increase the drug loading possibility
leading also to the opportunity of targeting ligands attachment for site-specific delivery
(Kamaly et al. 2012).
· The advantage of being used for various routes of administration including oral, nasal,
parenteral, intraocular etc. (Rai and dos Santos 2017)
In the past few years many NP types were developed to deliver different drugs to specific
target tissues also leading to a broader understanding of the mechanism of their uptake in the
brain and intracellular trafficking. Despite all this described theoretical potentials of
9nanosystems, a generation of nanotrasporters with broad possibilities of drug
functionalization, high delivery efficiency and high biocompatibility is not available yet.
1.4 From protein-based nanomaterials to dendronized streptavidin bioconjugates
Among the many types of NPs developed over time, natural biomolecules-based nanosystems
for therapeutic applications have gained an increasing interest in the scientific community due
to their biocompatibility, biodegradability and various possibilities for surface modifications
including the covalent attachment of targeting ligands and drugs (Wang and Uludag 2008).
Indeed, nature can be considered as an extraordinary library rich in chemical compounds
selected by evolution to match a great variety of biological functions. In biology, the molecular
self-assembly is a fundamental process governing the most important functions necessary for
life in all the organisms (Sgarbossa 2012). While thinking about the formation of cell
membranes or multi-protein complexes (eg. ribosomes, RNA polymerase) as well as the
folding of nucleic acids or proteins from polypeptide chains, it becomes clearer and clearer
the fascinating potential of biomolecules. Proteins represent the most abundant molecules in
biological systems. There are twenty different aminoacids that can get combined forming a
large diversity of proteins playing a broad set of biological functions. Thus, biomedical
strategies using the inner biological properties of proteins started to be the focus of the work
of many researchers.
In the context of protein therapeutics  at the present, more than 130 different proteins or
peptides are approved for clinical use by the US Food and Drug Administration (FDA), and
many more are in development. Protein therapeutics have several advantages over small-
molecule drugs. First, proteins often serve a highly specific and complex set of functions that
cannot be mimicked by simple chemical compounds. Second, there is often less potential for
protein therapeutics to interfere with normal biological processes and cause adverse effects.
Third, these agents are usually well-tolerated from the body since they are naturally produced;
indeed, they are less likely to elicit immune responses. Fourth, the clinical development and
FDA approval time of protein therapeutics may be faster than that of small-molecule drugs.
Thus, proteins becomes extremely attractive also from a financial perspective compared with
other small-molecule drugs, which it is a point not to be underestimated in designing new
compounds for clinical applications (Lagassé et al. 2017).
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The inordinately complex arrangement of aminoacid repeating unit chemistry, perfectly
sorted with 3-dimensional order in a confined nanometer volume and the peculiar structure-
function relation of proteins became new leading principles in nanotechnology pushing the
polymer chemistry to explore more efficiently the field of biomedical applications of synthetic
polymers (Cole et al. 2017, Duncan 2006).
Today, the term “polymer therapeutics” describes polymeric drugs, polymer-drug conjugates,
polymer-protein conjugates and multicomponent poliplexes. Such bio-nanotechnologies are
raising the hope that it will help realize the full therapeutic potential of the post-genomic era.
An advantage for polymer therapeutics compared to other nanosystems is the versatility of
synthetic chemistry, which allows tailoring of molecular weight, addition of biomimetic
features to the backbone construct and the opportunity of including bioresponsive elements.
The last decades have seen research at the interface of polymer chemistry and biomedical
sciences giving birth to the first nano-sized polymer-based pharmaceuticals (Duncan,
Ringsdorf and Satchi-Fainaro 2006). In this field, the advent of dendrimer chemistry has
brought many potential new prospects. Dendrimers are highly symmetric, spherical,
hyperbranched molecules with well-defined, homogeneous and monodisperse structure
carachterized by a typically symmetric core, an inner shell and an outer shell (Abbasi et al.
2014). They allow control over size, liquid solubility, a multitude of functionalization
possibilities, as well as the advantage of loading with different types of drug cargo. Their
chemical homogeneity, the possibility of increasing their size by repeated addition of chemical
moieties and a high density of surface groups that are suitable for ligand-attachment make
them an exceptional candidate for various biomedical applications (Gothwal et al. 2015).
Additionally, over time, the increasing number of studies revealed new inherent therapeutic
potential of denrimers (antiprion, antitoxin, and antiamyloidogenic effects (McCarthy et al.
2013, Lim et al. 2010, Förstner et al. 2014, Klementieva et al. 2013)). These achievements
became of great interest also for neuroscientists exploring dendrimers biomedical
applications for treatment of neurological disorders. Many dendrimer-drug-conjugates have
been introduced to the scientific community in the last years bringing new advances for
example in treatment of glioblastoma (G3-succinamic acid dendrimer- curcumin (Gamage et
al. 2016)), hypoxia (HIF-1α siRNA/2G-NN16 carbosilane dendrimer (Posadas et al. 2009)),
Parkinson´s disease (dendrigraft poly-L-lysine- PEG-Angiopep (Huang et al. 2013)).
Furthermore, several studies highlighted the positive effects of PAMAM dendrimers
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treatments on neuroinflammation in mouse either canine models of cerebral pulsy as well as
Rett syndrome although letal outcomes could not be avoided (Dai et al. 2010, Zhang et al.
2017). However, some cases drew attention to the need of very careful evaluation on the
biocompatibility of dendrimers. Indeed a representative case for this controversy is the work
of Klementieva and colleagues providing  poly(propyleneimine) (PPI) glycodendrimers which
exhibits good antiamyloidogenic effects but at the same time cause cognitive decline in WT
mice (Klementieva et al. 2013).Thus, despite the investigated and described dendrimer
systems for CNS applications, dendrimers with high biocompatibility as well as new linker
strategies and possibilities to transport biologicals (e.g. therapeutic proteins) for optimized
CNS diseases application are still an unmet need as highlighted in the review articles by Leiro
et al. and Mignani et al. (Leiro et al. , Mignani et al. 2017).
In this doctoral work, the ability to cross the BBB of multifunctional dendrimer-protein  which
mimics endogenous proteins with a size of 5 nm and a patched surface using a streptavidin
adapter coated by poly-amidoamine (PAMAM) dendrimers (DSA, dendronized streptavidin)
was evaluated (Figure 3). DSA were designed, synthesized and kindly provided by Dr. David
Ng working in the group of Pr. Dr. Tanja Weil at the Max Planck Institute for polymer research.
Figure 3.  Scheme of dendronized streptavidin assembly. The detailed G3
dendron structure is given (modified from Moscariello et al., 2018).
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1.4.1 Streptavidin: a flexible scaffold for biomaterials assembly
Streptavidin (SA) is a 56 KDa homotetramer from the bacterium Streptomyces
avidinii that binds up to four biotin molecules with an extraordinary high affinity (Kd
~ 10-14 M). The protein is unusually stable against heat, denaturants, extremes of
pH and to activity of proteolytic enzymes. These properties have rendered
streptavidin an outstanding tool for the different bioscientific fields. The tenacious
protein-protein interaction between SA and biotin opened the door to the
development of many applications. Thus, most SA-based applications require
biotinylation of target molecules. In recent years, many improvements have been
reached in biotinylation techniques, both chemical and enzymatic, which have
played an important role in advancing the SA-biotin technology in new areas (Jain
and Cheng 2017).
Since the core of a dendrimer is generally inconsequential towards targeting and recognition,
substituting it with a protein core provides an elegant approach towards both synthesis and
biocompatibility without compromising the monodispersed nature of both species. The
system presented here achieves the possibility to modulate the positive charge on the surface,
which is important for membrane-protein interaction and cellular uptake.
To our knowledge, the presented simple and elegant dendrimer system would allow for the
first time to employ both the inherent therapeutic functions of PAMAM dendrimers described
above (Lim et al. 2010, Förstner et al. 2014, Leiro et al. 2015) and therapeutic effects of
multiple drugs (including biologicals) in the same system attached to the streptavidin core by
biotin-click-chemistry.
1.5 From nanotheranostics to fluorescent Nanodiamonds
The development of nanosystems for biomedical application and drug delivery as well as the
discovery of intrinsic peculiar properties of many nanomaterials such as unique imaging and
functionalization capability led to the emergence also of a new “branch” of nanotechnology:
the nanotheranostics. The term “nanotheranostics” defines compounds on the nanometer
scale potentially providing a synergistic combination of therapeutics with diagnostic agents
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(Jeelani et al. 2014, Kim, Lee and Chen 2013).  Taking disease diagnosis in its strictest sense,
the adequacy and the actual suitability of nanotheranostics is disputable. Indeed,
nanotheranostics should be interpreted more as the action of monitoring the route and the
therapeutic efficacy of a given drug (real time drug distribution monitoring), or the prediction
of a potential treatment response. This approach also aims to reduce side effects achieving a
sufficient concentration of the therapeutic agent in the target and a maximum tolerable
concentration in off-target organs and to switch from conventional to personalized medicine,
also optimizing treatment costs (Jeelani et al. 2014, Lammers et al. 2010). At the moment,
several different types of radionuclide-labeled antibodies, liposomes, polymers and micelles
have been subjected to biodistributional analysis over the years, both in animal models and
in patients, and it has become clear that such studies substantially assist in improving our
understanding of the drug delivery process, as well as in predicting the therapeutic potential
of mostly tumor-targeted nanomedicines (Kievit and Zhang 2011, Lammers et al. 2010). Many
nanomaterials have been shown to be extremely useful for theranostics applications. For
example the unique physical properties, chemical versatility, and cargo loading capacity of
carbonaceous nanoparticles were particularly discussed in their use as potent cancer
therapeutics. For instance, most of these carbonaceous nanomaterials possess strong
absorption in the infrared or near infrared regions, which is useful for phototermal therapy of
cancer and drug response monitoring. Some of these inorganic nanomaterials (e.g., carbon
nanotubes or nanodots, nanodiamonds) can also produce fluorescence in the visible and
infrared regions for fluorescence imaging. In addition, carbonaceous nanomaterials are able
to transform the energy from a laser into acoustic signals, which makes them promising agents
for photoacoustic imaging. Finally, intrinsic Raman vibration signals from carbonaceous
materials can further provide a reliable method to monitor their distribution and metabolism
in vivo (Chen et al. 2015, Kim et al. 2013).
1.5.1 Nanodiamonds as suitable nanotheranostics agents
Nanodiamonds (NDs) are a new very promising class of carbon nanocompounds for
nanotheranostics, which I would like to introduce in more details. NDs are
characterized by peculiar optical and magnetic properties, biocompatibility, high
thermal conductivity and electrical resistivity, chemical stability and resistance to
harsh environment.
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Nanoscale diamond particles were first produced by detonation in the USSR in the
1960s, but they remained essentially unknown to the rest of the world until the end
of the 1980s. Researchers started to use fluorescent NDs (fNDs) as a non-toxic
alternative to semiconductor quantum dots for biomedical imaging. Then,
nanoscale magnetic sensors based on NDs were designed. New environmentally
benign purification techniques were developed and these allowed high purity NDs
powders with controlled surface chemistry to be produced in large volumes at a low
cost. The implementation of elemental defects (e.g. nitrogen vacancy) in the
internal structure leads to a stable and size-independent fluorescence
(Balasubramanian et al. 2008, Mochalin et al. 2011). Nitrogen vacancy (NV), a
nitrogen atom next to a vacancy, can be created by irradiating NDs with high-energy
particles (electrons, protons, helium ions), followed by vacuum annealing at 600-
800 °C. Irradiation forms vacancies in the diamond structure, and during annealing
these vacancies migrate and get trapped by the nitrogen atoms that are always
present in diamond. Recently, NDs have been shown to improve the sensitivity of
MRI thanks to their dynamic nuclear spin polarization and the presence of NV
centers (Wu et al. 2016).
Finally, NDs were found to be less toxic than other carbonaceous nanomaterials and
do not have noticeable side effects in vivo as in vitro thus are currently being
considered for applications in biomedical imaging, drug delivery, and other areas of
medicine (Zhu et al. 2012). In the field of neuroscience NDs have gained increasing
interest because of their structural similarity to memantine, a well known
neuroprotective drug commercially available for treatment of AD. Alawdi and
colleagues have clearly demonstrated in a rat model that NDs strongly mitigate the
pathological aberrations AD-related suggesting a NDs-dependent modulation of N-
methyl-D-aspartate (NMDA) receptors (Alawdi et al. 2017). Unfortunately the high
potential of NDs in biomedicine is strongly limited by their tendency to aggregate.
Currently typical commercial suspensions of NDs contain larger aggregates
hindering their biological applicability (Mochalin et al. 2011).
In the second part of this doctoral thesis the ability of fNDs encapsulated by a
cationized human serum albumin-based biopolymer (dcHSA-fNDS) to cross the BBB
and reach the brain in vitro and in vivo was evaluated (Figure 4). dcHSA-fNDs were
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designed by Dr. Yuzhou Wu (Wu et al. 2015), synthesized and kindly provided by
Weina Liu and Marco Raabe from the group of Prof. Dr. Tanja Weil at the Max Planck
Institute for Polymer Research, Mainz.
Figure 4.  dcHSA-fNDs synthesis. Scheme of dcHSA-fNDs encapsulation by HSA-
based polymer (modified from (Wu et al. 2015)).
1.5.2 Albumin, a carrier system
Albumin-based nanoparticle carrier systems represent an attractive strategy, since
a significant amount of drug can be incorporated into the particle matrix because of
the different drug binding sites present in the albumin molecule. Due to the defined
albumin primary structure and high content of charged aminoacids, albumin-based
nanoparticles could allow the electrostatic adsorption of positively or negatively
charged molecules. Additionally, albumin NPs can be easily prepared under soft
conditions by coacervation, controlled desolvatation or emulsion formation.
Commercially, what makes albumin a more charming molecule is that it can be
obtained in high quantities from egg white, bovine serum and human serum and it
is also available from soybeans, milk and grains (Khanadeev et al. 2017, Elblbesy
2016). Due to its high concentration in plasma, human serum albumin (HSA) is not
associated to significant extents with safety or immunogenicity concerns. In
addition, HSA is not a standard protein since it is extremely robust towards pH
(stable in pH range of 4-9), temperature (can be heated at 60 °C for up to 10 h) and
organic solvents. These properties as well as its preferential uptake for example in
tumor or inflamed tissues, its ready availability, biodegradability and lack of toxicity
make it an ideal candidate for drug delivery (Karimi et al. 2016). In nanotechnology,
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coating of NPs with HSA can be used for effective incorporation of various drugs due
to its extraordinary ligand binding capacity, providing a scaffold for a wide variety
of compounds for transport in the body and release at the cell surface (Vismara et
al. 2017). Furthermore, albumin-based NPs are expected to be well tolerated, which
is supported by previously published clinical studies with registered HSA-based
formulations such as AlbunexTM and AbraxaneTM (Geny et al. 1993, Ibrahim et al.
2002).
Although theranostics is giving much improvement in several scientific fields, such as cancer
therapy as just discussed above, the development of neurological diseases nanotheranostics
approaches represents still a great unsolved challenge. The ability to deliver imaging agents
and therapeutics across the BBB using NPs has the potential to transform the field of
neurological disease, and may be the key to cure some diseases that currently have
inadequate treatment options.
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2. Aim of the study
Neurological disorders have a high social impact due to severe morbidity and mortality. The
blood-brain barrier (BBB) represents the biggest hurdle to overcome in the drug development
process for neurological disorders. Of particular need are biocompatible platforms, which can
be loaded with multiple drugs to reach the target site: the brain. The aim of this study is to
evaluate two nanosystems in their ability to overcome the BBB in order to deliver therapeutics
or diagnostic tracers to the brain. The first system, DSA, is composed of an adapter of
tetrameric streptavidin linked to biotinylated PAMAM dendrimers suggesting high flexibility
and high drug loading possibilities via biotinylation of cargo-molecules. The second system,
dcHSA-fNDs, is composed of a fluorescent nanodiamond core coated with a human serum
albumin-based biopolymer, giving rise to a potential nanotheranostics platform due to the
inner optical and magnetic properties of fNDs and the high functionalization capability of
serum albumin.
In this thesis the following scientific questions were addressed: (1) Are DSA and dcHSA-fNDs
taken up by NVU cells and transported in an in vitro BBB model from luminal to abluminal? (2)
Which are the underlying mechanisms of the transport? (3) Do DSA and dcHSA-fNDs affect
vitality of NVU cells and BBB integrity? (4) Are DSA and dcHSA-fNDs able to cross the BBB and
how are they biodistributed in vivo?
These questions needed to be addressed to finally evaluate the investigated nanosystems for
possible biomedical applications in treatment of neurological disorders, still presenting a lack
of efficient therapies.
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3. Materials and Methods
3.1 In vitro assays for evaluation of BBB crossing capability of DSA and dcHSA-fNDs
As described by Wilhelm and Krizbai in their exhaustive review article about BBB models, the
best way to study the BBB is unquestionably in vivo. Given that in vivo experiments are
becoming more and more expensive and less suitable for medium or hightroughput screening,
the development of advanced BBB in vitro models provided a simple and efficient way to study
BBB functions and drug discovery. Indeed, in vitro models fulfil the most important criteria
required by pharmaceutical industry. Obviously, the development of these simplified models
needs the acceptance of several compromises in terms of costs, capacity, time and predictive
value. The parameters that a good BBB model has to respect are mostly reproducibility, low
paracellular permeability and expression of functional transporters. Transendothelial
electrical resistance (TEER) measurement and apparent permeability (Papp) of marker
molecules represent the two most important criteria to be evaluated and taken into account.
Over time, many BBB models employing many different cell types have been investigated in
order to improve the in vitro modelling. The simplest models are mono-cultures of cerebral
endothelial cells on microporous membranes. The pores of the membrane allow exchanges of
solutes between the luminal and the abluminal compartments. The major disadvantage of
mono-cultures is represented by the absence of stimulating factors derived from other cellular
components of the NVU. This is the reason why co-culture models have been developed to
mimic the in vivo anatomy of the NVU inducing and maintaining barrier properties. In fact,
really important is the contribute of astrocytes during adulthood on the interendothelial
junctions, which determines permeability, and also on the modulation of transporter
expression. Astrocytes can be co-cultured with endothelial cells on the bottom side of the
microporous membrane allowing a direct contact between the two cell types via astrocytes
protrusion across the porous. However, due to the relatively low density of the pores, the
coverage of the endothelial surface is only a fraction of what can be observed in vivo. A second
option can be the seeding of astrocytes at the bottom of the well on the abluminal side of the
transwell system. This model configuration enables soluble factors to exert their effect. An
alternative approach is to use astrocyte-conditioned medium although in this case the
influence of endothelial cells on the release of different factors by astrocytes is excluded.
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Finally, a triple co-culture model is even more efficient in mimicking the in vivo BBB physiology.
In this model, pericytes, neurons or neuronal progenitor cells can be introduced. A novel triple
cell neurovascular unit model employing brain endothelial cells, astrocytes and neurons was
recently established and provided the inspiration for the model used in this doctoral thesis.
TEER values for this triple co-culture system increased with 35.9 % compared with
corresponding endothelial mono-culture. High expression of p-glycoprotein and decrease in
permeability were also observed.
About the endothelial cells involved in BBB in vitro models the choice can fall among many
different cell types. Primary cultures are the first choice for drug permeability studies. With
respect to the tightness of the barrier, primary porcine brain endothelial cells seem to be the
best. Unfortunately isolation of primary cells is often complicated and costly and the cells
might differ from batch to batch. Therefore, the use of reliable brain endothelial cell lines is
broadly accepted. One of the major problems of cell lines is the poor barrier property. Among
the many cell lines used in BBB models, bEnd.3 cells were shown to have relatively low
permeability and high expression of ZO1 as indicator of high expression of tight junctions,
compared for example to MBEC4 and bEnd.5 also commonly used in BBB in vitro models.
In order to obtain a model suitable for drug delivery studies, optimization of culture conditions
seem to be of crucial importance. Indeed, components of the culture medium might also
contribute to the formation of a tight barrier. In this respect, elevated intraendothelial cAMP
levels have been shown to be important. Hydrocortisone in physiological concentration is also
often used to improve barrier properties.
At the end of this introduction to BBB in vitro models, a clear statement seems to emerge:
there is no ideal model. Each one has its own advantages and disadvantages. Therefore, a
suitable and appropriate model has to be selected based on the specific study (Wilhelm and
Krizbai 2014).
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3.1.1 Culturing of bEnd.3 cells
The murine line, bEnd.3, from brain endothelioma (American Type Culture
Collection, Manassas, VA, USA) was cultured as recommended by the manufacturer
(Montesano et al. 1990). Cells were cultivated at a humidified atmosphere with 37°C
and 5 % CO2 in DMEM (Glutamax, gibco by life technology, Darmstadt, Germany)
supplemented with 10 % fetal calf serum (Biochrom, S0115) and 2 %
penicillin/streptomycin (Pen/Strep) (Invitrogen GmbH, Karlsruhe, Germany). Cells
were seeded with 80.000 cells per insert (0.3 cm2) or 100.000 cells per coverslip
(80.000 cells per coverslips for experiment on the identification of tunnelling
nanotubes).
3.1.2 Isolation of Porcine Brain Endothelial Cells (PBECs)
Porcine brains were obtained from butcher Färber in Alzey, Germany and incubated
on ice during the transport in temporary buffer (10 % HEPES, 1 % Pen/strep, 1 %
Ciprobay 200 Bayer, 1 % Fungizone). Primary brain microvascular endothelial cell
isolation was established during this doctoral thesis with modifications to the
previously described protocol by Freese et al (Freese et al. 2014). Brain hemispheres
were incubated 1 h on ice in incubation buffer (10 % HEPES, 1 % Pen/Strep, 1 %
Ciprofloxacin Kabi 400 mg/200 mg, 1 % Fungizone). Brain emispheres were placed
in petri dishes with PBS on ice. Meninges were removed; emispheres were washed
with PBS and the gray matter isolated and maintained in PBS, minced by scalpel,
collected in a 50 mL tube filled with PBS and centrifuged at 1400 rpm for 10 min at
4°C. PBS was removed and tissue slices were maintained for 30 min at 37°C in
digestion mix composed by 1 mL of DMEM, 20 mg of Collagenase IV (2ml)
(Worthington; LS004210) and 20 µg of DNase I (20 µL). During the incubation time
the pellet was resuspended by pipetting up and down 10 times every 10 min. PBS
was added to a final volume of 50 mL and the disaggregated tissue was centrifuged
(1400 rpm, 10 min, 4 °C). PBS was discarded and the pellet was resuspended in a
solution of 20 % Percoll (GE Healthcare; 17-0891-01) diluted in PBS in a final volume
of 50 mL and centrifuged at 2600 rpm for 1 hr at 4°C (without brake). The upper 40
mL were removed to maintain capillary fragments fraction, PBS was added up to 50
mL and centrifuged (1400 rpm, 10 min, 4°C). The supernatant was discarded and
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pellet resuspended in DMEM supplemented with 2 mg of Collagenase/Dispase
(Roche, 10269638061) and 20 µg of DNase I in a total volume of 2 mL collecting the
pellet from two emispheres and filtered by 100 µm cell strainer. Cell suspension was
maintained 10 min at 37 °C. PBS was added up to 50 mL and cell suspension
centrifuged (1400 rpm, 10 min, 4 °C). The small red pellet was resuspended in 2 mL
of PBS. 1 mL of the cell suspension was moved on a Percoll gradient previously
prepared (24 mL Percoll + 13 mL PBS + 2 mL 10x PBS centrifuged at 10000 x g for 2
hr at room temperature) and centrifuged (2600 rpm, 15 min, 10 °C, without brake).
The brain endothelial cell fraction floating in the ring on the top of the gradient was
moved in a new 50 mL tube. PBS was added up to 50 mL and the tube centrifuged
(1400 rpm, 10 min, 4 °C). The pellet was resuspended in EBM-2 medium (Lonza; CC-
3156) containing supplements (rhFGF-B, rhEGF, GA-100, Ascorbic Acid, R3-ICF-1,
Heparin, Hydrocortisone; Lonza; CC-4114A), 15 % FCS and Glutamine (0.863 mg mL-
1). The all obtained cells from 2 emispheres were seeded in 10 transwell inserts and
2 coverslips precoated with fibronectin (F1141, 5 µg mL-1). Finally, the brain
endothelial cells were selected by puromycin (Enzo; BML-GR312-0050) treatment.
At DIV 0 cells were treated with higher concentration of puromycin which was
decreased in the 2 following days (4 µg mL-1 at DIV 0, 3 µg mL-1 at DIV 1 and 2 µg mL-
1 at DIV 2). At DIV 4 puromycin treatment was removed and medium exchange
(without puromycin treatment) carried out every two days.
For characterization of porcine cell growth the cell monolayer has been monitored
during time and confluent cells were stained with zona occludens 1 (ZO1) as marker
for the tight junctions in order to visualize one main feature of tight brain
endothelial monolayers (Figure 5). Cells were growing in clusters at first (Figure 5,
white arrows). After 7 days in vitro they reached confluence forming a highly
connected monolayer of cells with high expression of tight junctions.
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Figure 5.  Culture of isolated PBECs. PBECs growth within seven days in vitro. Cells
were treated with Puromycin the first three days after isolation to purify culture
from pericytes. White arrows point PBECs clusters, red arrows point brighter
signals generated by dead cells. ZO-1 stained tight junctions at DIV 7; scale bar:
200 µm.
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3.1.3 Isolation of primary murine astrocytes
Primary astrocyte cultures were obtained from six mice (P3). Brains were isolated
and placed in a petri dish with HBSS on ice. Meninges were peeled off and the cortex
isolated in HBSS with the help of a dissecting microscope. The tissue was incubated
with 0.05 % trypsin/EDTA for 20 min. During the incubation time tissue was
resuspended by pipetting up and down 10 times every 10 min. The reaction was
blocked with 10 % horse serum (HS; S9135, Biochrom) in HBSS -/- (gibco by life
technology, Darmstadt, Germany) in a final volume of 10 ml. Tissue was
resuspunded , filtered by a 40 µm cell strainer and centrifuged (1000 rpm, 5 min,
4°C). Supernatant was discarded and the pellet resuspended in 10 mL of culture
medium (MEM supplemented with 10 % horse serum and 5 µg mL-1 gentamycin).
Cells were seeded on poly-ornithine (P4538) coated T75-flasks. After reaching
confluence, cells were split 1:3. Astrocytes were seeded with 100.000
cells/coverslip, 52.000 cells/well in IBIDI-8-Well-Chamber, 25.000 cell/insert (0.3
cm2).
3.1.4 Isolation of primary murine neurons
Primary neuronal dissociated cell culture from mice were obtained following the
protocol introduced by Kaech and Banker (Kaech and Banker 2006) and optimized
by Beaudoin and colleagues (Beaudoin et al. 2012). Forebrains were collected from
three mice pups (P0-1) and meninges were removed. Tissue was washed three
times with maintaining solution (HBSS -/- supplemented with 5 mL Pen/Strep, 3.5
mL HEPES 1M pH 7.25, 1.5 mL Glucose 0.6 %, 5 mL sodium-pyruvate 100 mM) using
Pasteur pipette and incubated for 20 min in a 5 mL aliquot of a digestion mix
composed by 100 mL of 0.05 % Trypsin/EDTA (gibco by life technology, Darmstadt,
Germany), 1 mL Pen/Strep, 1 mL HEPES 1 M pH 7.25. During the incubation time the
tubes were carefully shaken every 5 min. DNase I (Roche, 11284932001) (2000 U in
5 ml) (500 µL) was added subsequently for 5 min at room temperature. After three
washing steps with maintaining solution, tissue was disrupted in 6 mL of Neuronal
Plating Medium (MEM, 10 % horse serum, 0.6 % glucose; 2ml/mouse). Tissue was
dissociated using Pasteur pipette (20 times up and down; the orifice was made
smaller via a fire-flame). The cell suspension was filtered by 40 µm cell-strainer and
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cells stained with trypan blue (T8154) were counted. Primary neurons were seeded
with cell numbers of 60.000 cells/well in 96-well-plates, 200.000 cells/coverslip (SDS
treated and poly-ornithine coated) or 100.000 cells/coverslips (for experiment on
the identification of tunnelling nanotubes (TNTs)) in plating medium. After 30 min
medium was replaced with Neuronal Maintenance Medium [Neurobasal Medium
(gibco by life technology, Darmstadt, Germany) with 2 x 10-3 M Glutamine (gibco by
life technology, 25030024) supplemented with B27 Supplement (gibco, 17504044)].
Medium exchange has been carried out every 7 days by replacing one-third of the
medium with fresh Neuronal Maintenance Medium.
3.1.5 Preparation of triple co-culture BBB model
Triple co-culture were composed by endothelial cells seeded on the luminal side of
the transwell inserts (BD Fluoroblok TM Inserts, 0.3 cm2, pore size 3 µm, Corning
Incorporated, Corning, USA), astrocytes seeded on the abluminal side of the
transwell inserts and neurons seeded at the bottom of the abluminal compartment
as shown in Figure 6.
For the in vitro triple co-culture model P1 primary astrocytes were detached from
the T75 flask by trypsinization (3 mL Trypsin 0.05 %, 37 °C, 5 min). After adding 10
mL of astrocytes medium, cell suspension from 3 flasks was collected in a 50 mL
tube and centrifuged (1000 g, 10 min, 4 °C). Supernatant was discarded and the
pellet resuspended in 5 mL of astrocytes medium. Cells were counted and seeded
on day 0 with a cell number of 25.000 cells/insert on the abluminal side of the
permeable transwell membrane by inverting the inserts on a big petri dish and
dropping 100 µL on the abluminal side of the semipermeable membrane. The
inserts were incubated inverted for 1 h at 37 °C. Then, inserts were placed in the
appropriate 24-well plate (Corning, 353504) adding 200 µL of astrocytes medium in
the luminal compartment. Additionally  25000 cells/coverslip were seeded and
coverslips placed at the bottom of the abluminal compartment in 900 µL of
astrocytes medium. The neurons were grown separately on CS. On day 2-3 bEnd.3
cells (passage 10-30) were seeded with 80.000 cells/insert in the luminal side of the
semipermeable membrane of transwell inserts. Co-cultures of astrocytes and bEnd.
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3 cells were grown in EBM-2-Basal-Medium (Lonza, Walkersville, USA)
supplemented with + 15 % FCS, Glutamine (0.863 mg mL-1) and EBM-2 Single Quot
Kit without VEGF growth factor. TEER was measured by Evom/Endhom chamber.
TEER of at least 27.5 Ωcm2 on day 9-11 was the quality benchmark for further usage
in vitro transport assay. On day 9-11 of co-culture and DIV 7-9 of neuronal culture,
inserts were combined with neurons on coverslips in abluminal compartment. For
transport assay TEER was monitored 24 h before and after DSA treatment.
Figure 6.  Scheme of triple co-culture BBB in vitro model. Endothelial cells were
seeded on the luminal side of the transwell inserts, astrocytes seeded on the
abluminal side of the transwell inserts and neurons seeded at the bottom of the
abluminal compartment.
3.1.6 Evaluation of NPs transport across BBB
Transport of DSA or dcHSA-fNDs was investigated in transwell assay in vitro. For
relative transport evaluation of DSA a mono-culture of PBECs or a triple co-culture
system were used as described above; for determination of transport rates for
dcHSA-fNDs a simplified model employing a bEnd.3 mono-culture was adopted by
seeding cells on BD Fluoroblok TM Inserts (0.3 cm2, pore size 3 µm, Corning
Incorporated, Corning, USA) in phenol red free cell culture medium for bEnd.3 cells
and placed in CellZscope device for costant TEER monitoring (380 µL in luminal
compartment; 900 µL in abluminal compartment). NPs were luminal applied (45 µg
mL-1for DSAs; 30 µg mL-1for dcHSA-fNDs) when TEER values were at least 40 Ωcm2
for bEnd.3 monolayer and triple co-culture and 50 Ωcm2 for PBECs. Crossing rate
was quantified by rhodamine labelling of NPs. After 24 h treatment, luminal (100
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µL) and abluminal (3 x 100 µL) medium were transferred in a 96 well-plate and
fluorescence was measured with Infinite F1000 TECAN plate reader and the
percentage of crossing was calculated. Fluorescence intensity in medium collected
from the abluminal compartment of transwell system without cells was set to 100
%. Additionally, for DSA, due to differences in transport rates between PBECs
monolayer and triple-co-culture, luminal was taken into account in order to
calculate the estimated fraction of DSA incorporated in cells. The estimated DSA
cellular fraction was obtained as follows: estimated cellular fraction = DSA initial
fluorescence (abluminal + luminal fluorescence Inserts without cells) - DSA
abluminal fluorescence - DSA luminal fluorescence.
Apparent permeability (Papp) was also analyzed using FITC-Dextran 4 (FD4) (46944)
applied at a concentration of 100 µg mL-1to the luminal side of the transwell system.
After 24 h the abluminal medium (3 x 100 µL) was collected for FD4 fluorescence
measurement. FD4 concentration was determined respectively to a calibration
curve obtained by the fluorescence measurement of serial dilutions values. Thus,
the apparent BBB permeability coefficient was obtained according to Artursson et
al. 1990,(Artursson 1990) by the following equation:
Papp = dQ/dt * 1/A*C0 [cm/s].
dQ/dt is the amount of transported FITC-dextran per seconds (µg/sec.), A is the
surface area of the filter (0.3 cm2), C0 is the initial FITC-dextran concentration (100
µg mL-1).
3.1.7 Measurement of transendothelial electrical resistance
TEER in the in vitro triple co-culture system was determined by EVOM voltometer
with an Endohm chamber for 6 mm culture cups (World Precision Instruments,
Berlin). The final TEER value (Ω x cm2) was determined from measured ohm (Ω)
subtracted by the Ω values of insert without cells, multiplied by insert surface area
of 0.3 cm2. TEER and capacitance of the cell layer (Ccl) of mono-culture systems
(PBECs for DSAs; bEnd.3 for dcHSA-fNDs) on transwell insert (BD Fluoroblock TM
Inserts; luminal: 380 µL, abluminal: 900 µL) was automatically determined using
CellZscope device (NanoAnalytics, Münster, Germany). For PBECs, after one week
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when the TEER was in exponential phase, the culture medium was replaced by EBM-
2 containing supplements (rhFGF-B, rhEGF, GA-100, Ascorbic Acid, R3-ICF-1,
Heparin), 550 nM hydrocortisone, 250 µM pCPT-cAMP (C3912) and 17.5 µM RO 20-
1724 (Calbiochem; 557502) to induce TEER values (Figure 7) (Patabendige, Skinner
and Abbott 2013a, Rubin et al. 1991). DSA-NPs treatment have been carried out
after 3 h from pCPT/RO application in order to avoid TEER values drop before the
end of the 24 h NPs incubation.
Figure 7.  TEER induction via cAMP analogue application. TEER measurement of
PBECs seeded on transwell inserts. TEER was induced via application of pCPT/RO
(indicated by arrow) during the exponential phase of TEER increase. In the graph,
three representative TEER measurements of PBECs manolayer are shown.
TEER of a surface attached bEnd.3 monolayer was determined using an Electrical
Cell Impedance Sensing array (ibidi in cooperation with Applied BioPhysics,
Martinsried, Germany). Cells were seeded in an 8-well chamber (ECIS culture ware
8W10E, ibidi in cooperation with Applied BioPhysics, Martinsried, Germany) and
were challenged with DSA for 24 h, when cells reached maximal plateau impedance
values. For all the just described methods, TEER values at time point 0 h were set to
1 and data were expressed as relative values. The experiments on effects of DSA on
28
BBB integrity were performed in close collaboration with Dr. Jana Hedrich and Malin
Jansen (during her internship to obtain the title of Master of Science).
3.1.8 Analysis of NPs cell uptake
DSA or dcHSA-fNDs were applied to cell culture medium (45 µg mL-1 for DSA; 30 µg
mL-1 for dcHSA-fNDs) for 24 h when bEnd.3 cells monolayer or astrocytes were
confluent and neurons reached a stable stage of cellular specification (DIV 8-9). For
co-uptake studies DSA were applied in combination to 120 µg mL-1 transferrin-Alexa
Fluor 488 (T13342, Invitrogen) or 15 µg mL-1 cholera toxin B subunit-FITC (C1655).
After 24 h cells were fixed with PFA 4%. Astrocytes and neurons were additionally
stained respectively for glial fibrillary acidic protein (GFAP) and ß-III-tubulin or
neuronal nuclear antigen (NeuN).
3.1.9 Evaluation of cell vitality
Cytotoxity was investigated using the Alamar Blue cell viability assay or TUNEL
assay. Cells were DSA-treated for 24 h after reaching confluence for bEnd.3 cells, 80
% of confluence for astrocytes and at DIV 9 for neurons. For viability quantification
by Alamar Blue, cells were washed with HBSS-/- three times and Resazurin (R7017,
16.66 µg mL-1) diluted 1:60 in HBSS+++ (HBSS-/-, 10 mM glucose, 2 mM CaCl2, 1mM
MgCl2) (500 µL/well for a 24-well plate; 100 µL/well for a 96-well plate) was added
to each well. Two empty wells and two wells with cells treated with staurosporine
(1 µM) were used respectively for blank and positive control. After 1 h incubation
(37 °C, 5 % CO2), Alamar Blue fluorescence was measured spectrophotometrically
using Tecan Infinite F1000 plate reader (Tecan, Salzburg, Austria). Fluorescence
values were corrected to fluorescence of the blank represented by resazurin
solution without cells. Cell Viability (%) was related to untreated control cells (100
%).
Cytotoxicity was analyzed also by TUNEL assay (ROCHE, DNA Fragmentation Imaging
Kit, 06432344001, Mannheim, Germany), which allows simultaneous quantification
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of cell numbers and apoptotic cells. At the end of NPs treatment, the relative
amount of total and apoptotic cells was quantified using the DNA Fragmentation
Imaging Kit according to the user manual. The relative fluorometric TUNEL values
were measured with Infinite F1000 TECAN plate reader and relative values for cell
numbers and ratio of all groups were normalized to untreated control cells. Cells
treated with staurosporine (1 µM) were used for positive control. All experiments
were run at least 3 times in triplicates.
The experiments on effects of DSA on cell vitality (Alamar Blue and TUNEL assays)
were performed in close collaboration with Dr. Jana Hedrich and Malin Jansen
(during her internship to obtain the title of Master of Science)
3.1.10 Preparation of cell lysates
bEnd.3 cells treated after reaching confluence were collected in culture medium by
cell scraper and the suspension was centrifuged for 5 min at 4°C at 200 x g. After 3
x PBS wash, the pellet was dissolved in 1 volume of lysis buffer (50 x 10-3 M Tris; 150
x 10-3 M NaCl; 1 x 10-3 M EDTA; 1 % Triton-X-100) supplemented with protease
inhibitor (Roche, 1 tablet of PhosSTOP EASYpack and 1 tablet of cOmplete Tablets,
Mini EDTA-free, EASYpack in 10 mL of lysis buffer) and incubated 45 min on rotation
wheel at 4°C. After centrifugation for 5 min at 4°C at 13000 x g the supernatant was
collected. The pellet was also dissolved in 1 volume of lysis buffer to obtain the cell
pellet probe. Cell lysate and cell pellet probes were stored at -20°C.
3.1.11 Concentration of proteins in medium samples
Culture medium (100 µL) after transport assay from abluminal compartment was
centrifuged at 14000 x g using Amicon Ultra 10K centrifugal filter devices
(UFC501024; Millipore) (1 centrifugation of 20 min, 1 centrifugation of 10 min, 1
centrifugation of 15 min) to concentrate the protein in a volume of 20 µL according
to the provided protocol.
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3.1.12 Protein detection by Western Blot
Samples were separated by electrophoresis (2000 mA, 175 V, 1h) on a SDS-
Polyacrylamide gel (12 % self-made or NuPAGE 4-12 % Bis-Tris Gel) and transferred
(3000 mA, 30 V, overnight) onto a polyvinylidene difluoride membrane (Roth,
T830.1; pore size: 0.45 µm). The membrane was blocked 30 min with 4 % non-fat
milk in TBST (500 x 10-3 M Tris base; 1.5 M NaCl; pH 7.2; 0.1 % Tween 20). Antibodies
against streptavidin (ab10020; 1:500; Abcam), LC3 (mab LC3-2G6; 1:200; Nanotools)
or GAPDH (A300-641A, 1:5000, Bethyl Laboratories) diluted in 4 % non-fat milk in
TBST were applied and incubated 5 h at room temperature. Finally, the protein of
interest was detected after 30 min incubation with HRP-conjugated anti-mouse
antibody (115-035-003; 1:5000; Dianova) or HRP-conjugated anti-rabbit antibody
(111-035-144; 1:10000; Dianova) and visualized on ChemiDoc XRS+ (BioRad) by ECL
Western Blotting substrate (Merck Millipore) according to the provided protocol.
Proteins were quantified by densitometric analysis. The bands of the protein of
interest were normalized respectively to the GAPDH band intensity of the same
sample/column by using the appropriate densitometric quantification tool of Image
Lab software (BioRad). Fold increase of protein of interest was expressed in relative
values compared to the CTR.
3.1.13 Analysis of autophagy induction
bEnd.3 cells were treated for 24 h with DSA (45 µg mL-1) or dcHSA-fNDs (30 µg mL-
1)  in a 24 well/plate. During the last 4 h of the 24 h treatment period, cells were
challenged with bafilomycin A1 (BAF; 400 x 10-9 M) to inhibit
autophagosome/lysosome fusion. Cell lysates were then used for WB detection of
endogenous LC3-II.
3.1.14 Analysis of DSA short-term lysosomal degradation
bEnd.3 cells in 24 well/plate were treated after reaching confluence with DSA (45
µg mL-1) for 24 h. BAF co-treatment (400 x 10-9 M) was applied simultaneously or
only in the last 4 h of the DSA treatment to inhibit lysosomal entrapment and
degradation of DSA. DSA-streptavidin core was detected by WB on cell lysates.
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3.1.15          Characterization of dcHSA-fNDs transport along TNTs
bEnd.3 cells (80000 cells/CS) or immature neurons/glia co-cultures  (DIV 2) were
treated with dcHSA-fNDs (30 µg mL-1) for 24 h. Cells were washed with PBS and fresh
medium was replaced to start the live cell imaging. For neurons/glia co-cultures,
after washing step, the medium was replaced with medium from a CTR CS due to
high sensitivity of primary neuronal culture to deprivation of growth factor
produced during culturing. 45 minutes live cell imaging was carried out by IX81
microscope and a monochrome ﬂuorescence CCD camera XM10 using the cellˆF
Software (Olympus). Movie speed was changed using Windows Live Movie Maker
to clearly visualize intracellular movements over time. Cells were further stained
with rhodamine-Phalloidin (Invitrogen, R415, 1:40) to visualize TNTs by actin fibers
staining. In case of neurons/glia co-cultures, in addition to rhodamine-phalloidin
astrocytes and neurons were stained respectively with GFAP and NeuN by
immunohistochemistry.
3.2 In vivo assays for evaluation of BBB crossing capability and biodistributional studies
of DSA and dcHSA-fNDs
All experimental procedures were approved by the ethical committee of the
“Landesuntersuchungsamt Rheinland-Pfalz” and the authority “Landesuntersuchungsamt
Rheinland-Pfalz”; protocol number: “Aktenzeichen 23 177-07/A_2010_05_07” and “23 177-
07/G 16-1-024”. Principles of laboratory animal care (European, national and international
laws) were followed.
3.2.1 Intravenous injection of NPs in mice
Fluorescent NPs were injected via the tail vein at a concentration of 450 µg mL-1
blood ( 900 µg mL-1 blood for NP-positive cells determination) for DSA and 500 µg
mL-1 by two serial injections at a time distance of 1 h for dcHSa-fNDs in P21 (DSA)
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or P29 (dcHSA-fNDs) mice. PBS-injected mice were used as CTR. As for in vitro
studies, the duration of the treatment has been kept with 24 h treatment.
3.2.2           Tissue harvesting for NPs uptake analysis by confocal imaging
 After the 24 h treatment, mice were deeply anesthetized (120 mg Ketamin/kg and
16 mg Xylazin/kg) and perfused with PBS supplemented with 5000 E.I. heparin-
natrium (Ratiopharm) in a total volume of 500 mL and subsequently with PFA 4 %.
Brain was collected as well as liver, kidney, spleen, lung and heart. Organs were
incubated overnight in PFA 4 % for post-fixation. Subsequently, organs were washed
three times with PBS and equilibrated in 30 % sucrose (in PBS 0.1 M, pH 7.5) for 20
up to 90 h. 30 µm slices were obtained using a freezing microtome (Leica CM 1325)
and used for immunohistochemistry studies.
3.2.3 Preparation of brain lysates and quantification of DSA in vivo brain
uptake
After treatment and perfusion with PBS/heparin (Ratiopharm), the collected brain
was smashed by TissueRuptor (Qiagen) in lysis buffer (50 x 10-3 M Tris; 150 x 10-3 M
NaCl; 1 x 10-3 M EDTA; 1 % Triton-X-100) supplemented with protease inhibitor
(Roche, 1 tablet of PhosSTOP EASYpack and 1 tablet of cOmplete Tablets, Mini
EDTA-free, EASYpack in 10 mL of lysis buffer). In order to obtain the brain lysate, the
homogenate was maintained on rotation wheel 3 h at 4°C and then centrifuged for
5 min at 2000 x g. Supernatant was collected and used for WB analysis. For
fluorometric quantification of DSA in vivo transport, brains were additionally
weighted after perfusion. After the incubation at 4 °C, samples were sonicated (7
cycles of 30 sec) and centrifuged 10 min at 4000 x g. Cy5-fluorescence for G3-DSA
was measured by Tecan Infinite F1000 plate reader. % ID and µg / g of brain tissue
of transported G3-DSA were calculated referring the fluorescence values to a
calibration curve obtained via serial dilutions of Cy5-DSA in brain lysates (Nance et
al. 2016).
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3.2.4 Evaluation of BBB integrity by Evans Blue (EB) extravasation assay
EB (MW 961 Da) is an intravital dye that in blood binds to the albumin fraction (EBA)
to give rise to a high-molecular complex (EBA = 68,500 Da) unable to cross an intact
BBB (Kozler and Pokorný 2003).
Thus, to study in vivo BBB integrity a solution of 2 % Evans Blue (E2129) in PBS was
administered i.v. for 3 h before the end of NPs treatment. Mice were perfused with
PBS/heparin for biochemical EB detection or collected without further perfusion
for histochemical analysis. One emisphere from the perfused brain for biochemical
EB detection was weighted and incubated in 500 µL of TCA (8789, Roth) 50 %
diluted in water. The brain emispheres in TCA were then smashed by TissueRuptor
(Qiagen) and incubated overnight. The day after, the samples were centrifuged for
25 min at 12000 x g. Supernatant was collected and 2 x 200 µL were loaded in a 96-
well-plate for EB fluorescence measurement by Infinite F1000 TECAN plate reader.
EB (µg)/brain tissue (g) was calculated referring to a calibration curve in a range
from 0 to 1 µg mL-1 of EB in TCA.
Brains without perfusion were incubated in PFA 4 % overnight and cut in 30 µm
slices as previously described for NPs uptake analysis in vivo. In case of BBB
disruption histochemical results would show EB permeation and uptake in brain
parenchyma (Figure 8).
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Figure 8.  Evans Blue application and brain extravasation. (A) Scheme of EB
application and distribution 3h after injection in mice. (B) Examples of EB
extravasation in the brain. EB is observable by eyes in mice brains with disrupted
BBB compared to sham animal and its extravasation is shown microscopically by
EB fluorescence detection; in epifluorescence pictures EB is shown in red and cell
nuclei in blue (modified from Braniste et al. 2014).
3.3 Immunocytochemical and histochemical analysis
Cells or organs were fixed with PFA 4 %. Organs were sliced in 30 µm slices. Probes were
blocked and permeabilized with 7 % normal donkey serum (Dianova, Hamburg, Germany)/ 0.3
% (0.8 % for organ slices) Triton (T-8787) in PBS for 2 h at RT. If the first antibody was from
mice, organ slices were at first incubated with donkey anti-mouse FAB fragment (Dianova,
715-007-003, Hamburg, Germany) in PBS 0.01 M for 2 h at RT. Primary antibody was incubated
in 2 % bovine serum albumin (Dianova, 001-000-161, Hamburg, Germany) with 0.05 % azide
and 0.1 % (0.3 % for organ slices) Triton/PBS overnight at RT. After three washing steps,
secondary antibody and DAPI (32670) were incubated in 2 % bovine serum albumin with 0.05
% azide for 2 h at RT, followed by PBS washing. Organ slices were additionally washed with
Tris-HCl 0.05 M at pH of 6.5. Cells or slices were finally embedded respectively in Fluoromount
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(Biozol, Eching, Germany) or CFM-3R (Citifluor Ltd., London, UK) to reduce tissue background
fluorescence.
Table1. Antibodys for immunohistochemistry
Primary antibody Secondary antibody
ZO-1
anti-zonula occludens 1 (rabbit, Zymed via
invitrogen, 61-300, 1:100)
Cy2 goat anti-rabbit IgG (Dianova, 111-25-
144, 1:10)
EEA
anti-early endosome antigen-1 (rabbit,
Abcam, ab50313, 1:50)
Alexa Fluor 647 donkey anti-rabbit IgG (
Jackson, Dianova, 711-605-152, 1:200)
LAMP1
anti-cluster of differentiation 107a (rat, BD
Biosciences, 553792, 1:50)
DyLight 488 donkey anti-rat IgG (Bethyl Lab,
Biomol, 1:200)
VAMP3
anti-vesicle-associated membrane protein 3
(rabbit, Synaptic System, 1:250)
Cy2 donkey anti-rabbit IgG (Jackson,
Dianova, 711-225-152, 1:200)
TfR
anti-transferrin receptor (mouse, Zymed via
Invitrogen, 1:500)
Dylight 488 donkey anti-mouse IgG (Bethyl
Lab, Biomol, A90-337D2, 1:200)
LC3
anti-microtubule-associated protein 1A/1B-
light chain 3 (mouse, Nanotools, 0260S/LC3-
2G6, 1:200)
Dylight 488 donkey anti-mouse IgG (Bethyl
Lab, Biomol, A90-337D2, 1:200)
GFAP
anti-glial fibrillary acidic protein (mouse,
Synaptic Systems, 173011, 1:1000)
Dylight 488 donkey anti-mouse IgG (Bethyl
Lab, Biomol, A90-337D2, 1:200)
NeuN Dylight 488 donkey anti-rabbit IgG (Jackson,
Dianova, 711-485-152, 1:200)
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anti-neuronal nuclear antigen (rabbit, Merck
Millipore, ABN78, 1:500)
CD105
anti-endoglin (rat, Beckman Coulter,
732334, 1:50)
DyLight 488 donkey anti-rat IgG (Bethyl Lab,
Biomol, 1:200)
3.4 Image processing and analysis
Images were taken by an IX81 microscope and a monochrome fluorescence CCD camera XM10
using the cellˆF Software (Olympus) or by a TCS SP5 confocal (Leica). For quantification of
intracellular colocalization, Z-stacks were deconvolved by Huygens Essential software. For
uptake quantification in ImageJ, fixed thresholds were applied for DAPI and rhodamine signal
and fluorescence positive particles were counted for each image. DSA positive vesicles per cell
are blotted. For colocalization studies the percentage of vesicles containing nanoparticles
colocalizing with the specific intracellular compartment was calculated. A threshold of 40 % of
colocalization for each vesicle was set to avoid false positive values. In addition, deconvolved
z-stacks were also analyzed by JacoP plugin in ImageJ to calculate Van Steensel´s
crosscorrelation functions (CCFs) as proof of colocalization data.
3.5 Statistic data analysis
All data were analyzed with GraphPad Prism 5 software (Graph Pad, La Jolla, CA, USA) and
were presented as mean ± SEM. Data were analyzed with the Mann-Whitney U test, ANOVA
one way and ANOVA two-way with post hoc test.  P < 0.05 was considered as statistically
significant *, P < 0.01 **, P < 0.001 ***.
The in vitro experiments carried out with dcHSA-fNDs were performed in close collaboration
with Sandra Bernardt and partly included in her dissertation to obtain the title of Master of
Science.
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4. Results
4.1 Dendronized Streptavidin for brain drug delivery via crossing an intact BBB
4.1.1 DSA are taken up by brain endothelial cells in vitro
The tightly connected layer of brain endothelial cells represents the first obstacle to
the entry of molecules into the CNS. Therefore, we investigated the ability of
differently charged generations of DSA (G2-DSA and G3-DSA) to be taken up by
bEnd.3 cells in vitro. After 24 h of DSA treatment, DSA-rhodamine signal was
detected by confocal microscopy and 3D reconstructions z-stacks were screened for
DSA uptake. The results showed DSA signal in the cell of treated samples compared
to control (CTR) untreated cells not as single-unit NP but as DSA-containing vesicles
(Figure 9A). The quantification of the DSA-containing vesicles showed significant
uptake for both generations of DSA with a significantly higher number of NP-
containing-vesicles for G3-DSA than for G2-DSA (CTR: 0 ± 0 vs. GS-DSA: 0.7 ± 0.7
vesicles/cell, CTR: 0 ± 0 vs. G3 5.2 ± 0.43 vesicles/cell, G3-DSA: 5.2 ± 0.43 vs. G2-
DSA: 0.7 ± 0.7 vesicles/cell, n = 28 regions of interest from 3 cultures, one-way
ANOVA, P < 0.0001) (Figure 9B). Due to the protein core of DSA, imaging data could
be confirmed by a biochemical approach. Indeed, western blot (WB) carried out on
cell lysate from DSA-treated cells showed cell uptake by streptavidin core detection.
NP signal was detected in cell lysate as well as in cell pellet (Figure 9C).
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Figure 9.  DSA uptake in bEnd.3 cells. (A) Confocal 3D-image of DSA (red) uptake.
(B) Quantification of DSA-positive vesicles per cell. n = 28 ROIs from 3 cultures,
one-way ANOVA, ***p < 0.001, *p < 0.05. (C) Streptavidin immunoblotting of cell
lysate after DSA uptake.
Uptake studies proved the uptake of DSA in the first cellular barrier: the endothelial
cells. Since this is the most critical part of uptake, we investigated further the co-
uptake of DSA with markers for caveolae- and clathrin-mediated pathways. The two
pathways were investigated, because, caveolae-mediated uptake is the most
common uptake mechanism in endothelial cells (Voigt, Christensen and Shastri
2014, Hillaireau and Couvreur 2009, Frank et al. 2003) and it has been demonstrated
that PAMAM dendrimers are taken up via a clathrin-mediated pathway (Albertazzi
et al. 2010). bEnd.3 cells were treated for 24 h with DSA in combination with FITC-
Transferrin (TF) for clathrin-mediated endocytosis and the subunit B of cholera
toxin-alexa-fluor-488 (CTX) for the caveolae-mediated endocytosis in order to
follow the two pathways. Confocal microscopy showed colocalization of DSA with
both investigated endocytosis markers (Figure 10A). Quantitative analysis on z-
stacks revealed that TF colocalizes for 7.9 ± 2.9 % of vesicles with G2-DSA and for
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7.6 ± 2.12 % of vesicles with G3-DSA (n = 20 regions of interest from 3 cultures,
Mann-Whitney U test, P = 0.8881) (Figure 10B). While, CTX showed a colocalization
of 32.7 ± 4.9 % of vesicles with G2-DSA and 42.3 ± 4.36 % of vesicles with G3-DSA (n
= 20 regions of interest from 3 cultures, Mann-Whitney U test, P = 0.2615) (Figure
10C). These data revealed uptake of DSA by both investigated mechanisms with no
significant difference between G2-DSA and G3-DSA, but with a pronounced
preference for the caveolae-mediated endocytosis (For G2-DSA = TF: 7.9 ± 2.9 % vs.
CTX: 32.7 ± 4.9 %  n = 20 regions of interest from 3 cultures, Mann-Whitney U test,
P < 0.0007; for G3-DSA = TF: 7.6 ± 2.12 %  vs. CTX: 42.3 ± 4.36 %  colocalization with
G3-DSA: n = 20 regions of interest from 3 cultures, Mann-Whitney U test, P <
0.0001).
Figure 10.  DSA uptake mechanism in bEnd.3 cells. (A) Confocal orthogonal view
of DSA (red) co-uptake with TF or CTX (green) in bEnd.3 cells. (B, C) Percentage of
colocalization of DSA with FITC-TF (B) or FITC-CTX (C). n = 20 ROIs from three
independent experiments, Mann-Whitney U test, ns = not significant.
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4.1.2 DSA are Efficiently Transported Across BBB In Vitro
After proving DSA uptake in bEnd.3 cells, to challenge the hypothesis of overcoming
the BBB with DSA, the transport of G2-DSA and G3-DSA from the luminal to the
abluminal side of two BBB transwell in vitro models was investigated. In the in vitro
models employed for this experiment the luminal compartment represents the
bloodstream and the abluminal compartment represents the brain. In one model
porcine brain endothelial cells (PBECs) were seeded in the luminal side of transwell
inserts in a monolayer system (Figure 11A). Moreover, transport of DSA was
validated in a murine triple co-culture system using bEnd.3 as endothelial cell lines
seeded on the luminal side of transwell inserts additionally to primary murine
astrocytes in the abluminal side and primary murine neurons on the bottom of the
abluminal compartment (Figure 11B). In order to investigate the ability of DSA to
cross the BBB, the percentage of transport as measurement of the rhodamine
fluorescence in the abluminal compartment after 24 h treatment was defined. All
the values referred to the 100 % of transport represented by the passive
permeation of DSA in transwell inserts without cells. In mono-culture, 15.7 ± 4.2 %
of G2-DSA (n = 6 wells from 3 cultures in duplicate) compared to 100 % G2-DSA (100
% ± 4.79, n = 6 wells from 3 cultures in duplicate, one-way ANOVA, P < 0.0001) and
19.2 ± 1.56 % of G3-DSA (n = 8 wells from 4 cultures in duplicate) compared to 100
% G3-DSA (100 % ± 2.29, n = 8 wells from 4 cultures in duplicate, one-way ANOVA,
P < 0.0001) were transported to the abluminal compartment (Figure 11C).
Comparing the two generations of dendrimers, no significant difference in transport
rates could be observed (G2-DSA: 15.7 ± 4.2 % vs. G3-DSA: 19.2 ± 1.56 %, n = 6-8
wells from 3-4 cultures in duplicate, one-way ANOVA, P > 0.05). Using triple-co-
culture, 37.8 ± 4.01 % of G2-DSA (n = 8 wells from 4 cultures in duplicate) compared
to 100 % G2-DSA (100 % ± 0.93, n = 8 wells from 4 cultures in duplicate, one-way
ANOVA, P < 0.0001) and 21 ± 1.69 % of G3-DSA (n = 8 wells from 4 cultures in
duplicate) compared to 100 % G3-DSA (100 % ± 2.3, n = 8 wells from 4 cultures in
duplicate, one-way ANOVA, P < 0.0001) were transported to the abluminal
compartment (Figure 11D) showing significant differences in transport rates for the
two investigated DSA-generations apparently with a more pronounced crossing
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ability for G2-DSA than for G3-DSA .  The protein content of the abluminal medium
was further concentrated via ultra 10K filter devices and a WB analysis was carried
out (Figure 11E). Thus, bands for G2-DSA and G3-DSA on PVDF membrane
confirmed the DSA transport via streptavidin core detection.
Figure 11.  Transport of DSA in vitro. (A-B) Schematic illustration of transwell
assay with endothelial cells seeded in mono-culture (PBECs) (A) or in triple co-
culture with bEnd.3 cells and murine primary astrocytes and neurons (B). (C-D)
Mean relative transport for DSA in porcine mono-culture (C) or triple co-culture
(D). DSA (45 μg mL-1) were applied in the luminal compartment and transport was
quantified relative to transport in insert without cells (100%). One-way ANOVA,
***p < 0.001; **p < 0.01, ns = not significant. Porcine mono-culture: G2-DSA, 100%
G2-DSA n = 6 wells from 3 cultures in duplicate; G3-DSA, 100% G3-DSA n = 8 wells
from 4 cultures in duplicate; triple co-culture: n = 8 wells from 4 cultures in
duplicate; one-way ANOVA, ***p < 0.001; **p < 0.01, ns = not significant. (E)
Streptavidin immunoblotting of abluminal medium. (F,G) TEER monitoring of NPs
transport assay. TEER values were determined automatically during the whole
experiment by CellZscope device (F) or at -24 h, 0 h and +24 h from NP application
by EVOM system (G). TEER values at t = 0 (DSA treatment) were set to 1 and each
measurement expressed as relative value. Porcine mono-culture: CTR n = 6 wells
from 3 cultures in duplicate, G2-DSA n = 6 wells from 3 cultures in duplicate, G3-
DSA n = 8 from 4 cultures in duplicate; TEER absolute values in a range between
50 and 300 Ωcm2. Triple co-culture: n = 8 from 4 cultures in duplicate; TEER
absolute values with a mean of 45 ± 13 Ωcm2.
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In order to understand if the differences in the transport rate between the two
models are attributable to preferential cellular uptake of G3-DSA, the estimated
DSA fraction incorporated in cells (estimated DSA cellular fraction = DSA initial
fluorescence - DSA abluminal fluorescence - DSA luminal fluorescence) was
determined (Figure 12). Interestingly, for G3-DSA in the triple co-culture model a
considerably higher fraction of fluorescence than mono-culture vanished from the
luminal and abluminal compartments (Figure 11A), while for G2-DSA the loss of
fluorescence was constant and comparable in both investigated BBB models (Figure
11B).
Figure 12. DSA estimated cellular fraction in BBB models in vitro. The graphs
present the three different fractions obtained for transwell models after 24 h of
G3-DSA (A) or G2-DSA (B) application in luminal compartment. Estimated cellular
fraction = DSA initial fluorescence – DSA abluminal fluorescence - DSA luminal
fluorescence. Co-culture: n = 8; mono-culture: n = 6.
To validate our in vitro transwell systems as suitable models to study the transport
of DSA, transendothelial electrical resistance (TEER) was monitored continuously by
CellZscope after PBECs cells seeding for monolayer model or by EVOM/Endhom
chamber for the triple co-culture. The TEER measurement before and after the
transport should prove the tightness of the used BBB models to be high enough to
consider transport data as reliable. DSA were applied when the absolute TEER
values fell in a range between 50 and 300 Ωcm2 for porcine modelor reached a mean
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value of 45 ± 13 Ωcm2 for triple co-culture. The TEER was not influenced by
treatment with DSA compared with t = 0 (time point of DSA application) (Figure 11F,
G). In the triple co-culture model the TEER even increased slightly during NP
treatment for 24 h (Figure 11G). Hence, no paracellular leakage due to disruption of
the BBB has to be expected. Since the tight junctions restrict the paracellular
diffusion of hydrophilic tracers, the Papp coefficient for FITC-dextran 4 KDa (FD4)
could be determined as additional validation parameter. Indeed, compounds like
FD4 can be used in order to monitor paracellular diffusion (Gaillard and de Boer
2000). The average basal Papp of FD4 was 9.24 ± 3.59 x 10-7 cm s-1 in our model
employing PBECs and 1.28 ± 2.21 x 10-6  cm s-1 in triple co-culture model. TEER and
Papp validations proved the good quality of the used BBB in vitro models to be used
for transport assessment of DSA.
4.1.3 DSA follow a transcytotic pathway without short term intracellular
degradation and involvement of autophagic mechanisms
The transport of DSA from the luminal to the abluminal compartment of the
transwell models implicates intracellular migration and trafficking which starts with
the already discussed uptake. The focus of this study is on the understanding of the
transcytotic pathway involved in the crossing of BBB.  The inner life of the cells is
characterized by high compartmentalization. Multiple intracellular structures and
organelles with their own identity and functions can be involved in trafficking and
transcytosis of nanoparticles. Hence, to clarify the molecular mechanisms how DSA
cross the BBB requires a close view on this mazy “microworld”. The localization of
DSA in cellular compartments was studied by using specific intracellular markers.
Co-staining with early endosome antigen (EEA) and lysosomal-associated
membrane protein 1 (LAMP-1) were analyzed in order to investigate the possible
localization of DSA respectively in early endosomes (EE) and late endosomes (LE).
Representative orthogonal view from z-stacks revealed colocalization with both
intracellular compartments in bEnd.3 cells after 24 h of DSA treatment (Figure 13A).
44
Figure 13.  Endosomal trafficking of DSA in bEnd.3 cells. (A) Confocal orthogonal
view for colocalization of DSA-positive vesicles (red) and early endosome antigen
(EEA; green) for early endosomes, lysosomal-associated membrane protein 1
(LAMP1; green) for late endosomes. Insets: zoom of ROIs with colocalization
(yellow). (B, C) Quantification of colocalization for DSA with early endosomes (B)
or late endosomes (C). Data are expressed in percentage of DSA-positive-vesicles
partially colocalizing for at least 40 % with endosomal vesicles. n = 24 ROIs from 3
cultures; Mann-Whitney U test, ***p < 0.001; ns = not significant.
Quantification of colocalization of DSA with EE revealed significant generation-
dependent differences (G2-DSA: 70.7 ± 3.73 % vs. G3-DSA 33 ± 3.12 %, n = 24 regions
of interest from 3 cultures, Mann-Whitney U test, P < 0.0001) (Figure 13B). In
contrast, colocalization of DSA with LE showed a lower percentage than for EE and
no difference between G2-DSA and G3-DSA (G2-DSA: 14.3 ± 1.51 % vs. G3-DSA: 15
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± 1.62 %, n = 24 regions of interest from 3 cultures, Mann-Whitney U test, P =
0.7947) (Figure 13C). Nonetheless, there were still NP containing vesicles that did
not colocalize with EE or LE. In order to study in which other intracellular
compartments DSA localized during trafficking, several other markers of vesicular
transport were tested. First, using immunocytochemistry,further experiments were
focused on the possible colocalization of DSA with transferrin-receptor (TfR) and
vesicle-associated membrane protein 3 (VAMP3) that has been postulated to be a
vesicle soluble N-ethylmaleimide-sensitive-factor attachment receptor (v-SNARE)
for early and mostly recycling endosomes, although mice with a null mutation in the
encoding gene were preserving intact endocytotic pathways (Hu, Hardee and
Minnear 2007, Yang et al. 2013). Tridimensional view obtained by confocal
microscopy did not reveal a colocalization of DSA with Tfr- and VAMP3-positive
intracellular structures (Figure 14).
Figure 14.  DSA intracellular trafficking in bEnd.3 cells. Representative confocal
tridimensional orthogonal view for colocalization analysis of DSA-positive vesicles
(red) and vesicle associated membrane protein 3 (VAMP3; green) (A) for recycling
endosomes or transferrin receptor (TfR; green) (B).
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Previous findings demonstrated that some biodegradable NP can induce autophagy
and be sequestered by autophagosomes (Zhang et al. 2016). Then, the possible
induction of autophagy and whether DSA localized or not in autophagosomes was
further investigated. bEnd.3 cells were stained with anti-microtubule-associated
protein 1A/1B-light chain 3 (LC3), which is a marker for autophagosomes. During
autophagy, double membrane autophagosomes assemble in order to engulf
intracellular components. A cytosolic form of LC3, LC3-I, is conjugated with
phosphatidylethanolamine during the process of autophagosomal membrane
formation and subsequently generates LC3-II which is recruited to autophagosomal
membranes (Loos, du Toit and Hofmeyr 2014, Tanida, Ueno and Kominami 2008).
Immunocytochemistry revealed that only very few NP-containing vesicles might
colocalize with autophagosomes (G2-DSA: 0.8 ± 0.46 vs. G3-DSA 1.8 ± 0.86 %, n =
17-20 regions of interest from 3 cultures; Mann-Withney U test, P = 0.0244) (Figure
15A, B).
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Figure 15.  Effect of DSA on autophagy in bEnd.3 cells. (A) Representative confocal
tridimensional orthogonal view for colocalization analysis of DSA-positive vesicles
(red) and microtubule-associated protein 1A/1B-light chain 3 (LC3; green). (B)
Quantification of colocalization for DSA with autophagosomes. Data are expressed
in percentage of DSA-positive-vesicles partially colocalizing for at least 40 % with
autophagosome-vesicles. G2-DSA n = 20 ROIs, G3-DSA n = 17 ROIs from 3 cultures;
Mann-Whitney U test, *p < 0.05. (C) Percentage of LC3-positive cells in CTR or DSA
treated bEnd.3 cells. Total number of cells in each analyzed ROI represents 100%.
n = 30 ROIs from 3 cultures; one-way ANOVA; ns = not significant. (D, E) Western
blot of lysates (D) and bands densitometric quantification (E) of LC3-II levels in CTR
and DSA-treated cells. Bafilomycin (BAF) was used as inhibitor of autophagosome-
lysosome fusion.n = 3 cell lysates from 3 cultures; one-way ANOVA; ns = not
significant.
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Autophagy can lead to contrary cellular fates because it is involved in both beneficial
and harmful cellular effects (Cherra and Chu 2008, Codogno and Meijer 2005).
While autophagy is activated at basal level in most of the cells in the body with a
role in regulating the turnover of long-lived proteins and eliminating damaged
structures, high levels of autophagy are often an indication of cellular stress. In
order to address the question of whether DSA treatment might affect cellular
homeostasis, induction of autophagy in bEnd.3 cells was monitored using
immunocytochemical and biochemical approaches. First, comparing the ratio LC3-
positive-cells/total number of cells in control culture and NP-treated samples, no
DSA-mediated induction of autophagy could be demonstratedDSA (CTR: 3.6 ± 0.44
%; G2-DSA: 2.8 ± 0.45 %; G3-DSA: 2.5 ± 0.35 %, n = 30 regions of interest from 3
cultures, one-way ANOVA, P = 0.1657) (Figure 15C). Additionally, LC3-II levels can
be analyzed to define activation of authopagic process, due to the fact that LC3-II
correlates with autophagosome numbers (Loos et al. 2014, Tanida et al. 2008). To
analyze the autophagic flux, the measurement of the LC3-II levels as a function of
GAPDH (loading control) was compared by WB. Bafilomycin A1 was used to inhibit
autophagosome-lysosome fusion to determine the activity of autophagic flux
(Mauvezin and Neufeld 2015, Yang et al. 2013). No increase in LC3-II levels was
observed in bEnd.3 treated with DSA for 24 h (CTR + BAF: 1; G2-DSA + BAF: 0.95 ±
0.14; G3-DSA + BAF: 0.85 ± 0.03, n = 3 from 3 cultures, one-way ANOVA, P = 0.4630)
(Figure 15D). Taken together, these data indicate no increase of autophagy in DSA-
treated cells with no incidence on the ratio of pro-survival/pro-death inputs.
The data presented so far demonstrated the transport of DSA by transcytosis. It has
to be considered that material taken up from extracellular space by endocytosis
often is delivered to lysosomes and there degraded by acid hydrolases. In order to
study, if DSA might be temporarily delivered to lysosomes and partly degraded, I
detected DSA by WB analysis in cell lysates after blocking the process of endosomes-
lysosome fusion with BAF (4 h and 24 h treatment). I did not observe any change in
levels of DSA uptake comparing BAF-treated samples with untreated ones (G2-DSA:
1, G2-DSA+BAF 4 h: 1.04 ± 0.18, G3-DSA: 1, G3-DSA+BAF 4 h: 0.97 ± 0.06, G3-
DSA+BAF 24 h: 1.02 ± 0.01, n = 3 from 3 cultures, one-way ANOVA, P = 0.9826)
(Figure 16A, B). In conclusion, the intracellular colocalization data presented herein
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confirm a transcytosis transport which preserves DSA integrity and might involve
lysosomal escape.
Figure 16.  DSA lysosomal degradation. (A) Streptavidin (STREP) immunoblotting
of lysate from CTR and DSA treated bEnd.3 cells. Bafilomycin (BAF) treatment for
4 h or 24 h was used to induce lysosomal escape of DSA. (B) Densitometric
quantification of STREP levels for DSA-treated cells with or without BAF treatment.
STREP levels of not BAF-treated samples were set to 1 and each correspondent
BAF-treatment expressed as relative value; n = 3 cell lysates from 3 cultures; one-
way ANOVA; ns = not significant.
4.1.4 DSA do not affect bEnd.3 cells vitality and BBB integrity
The ability of DSA to be taken up by endothelial cells and transported across BBB
has been assessed. The biocompatibility is another parameter that has to be
evaluated for NPs which are validated to be used in therapeutic approaches.
Indeed, the nanosystem presented here aims to target the brain without disruption
or opening of the BBB and without affecting cell viability. Cell viability was
challenged for 24 h with rising concentration of DSA (from 10 to 400 µg mL-1)
considering that the applied concentration for uptake and transport studies was 45
µg mL-1. Cell vitality quantified by reduction of the alamar blue viability reagent
showed no toxicity of the DSA for all concentrations (n > 9 wells from 4 cultures;
one-way ANOVA; P > 0.05). On the contrary, CTR and serial dilutions of DSA showed
high significant differences with the staurosporine probe used as toxic control (live:
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99.8 ± 0.75 %  vs. dead: 1.81 ± 1.37 %, n > 9 wells from 4 cultures, one-way ANOVA,
P < 0.05) (Figure 17A).
Figure 17  DSA effect on cell vitality and BBB integrity in vitro. (A) bEnd.3 cell
vitality by Alamar Blue assay after DSA treatment (24 h). Positive control: cell toxin
staurosporine. n > 9 wells from 4 cultures; one-way ANOVA; ***p < 0.001. (B, C)
Long term impact of DSA on cell integrity investigated for 72 h by ECIS. TEER values
at t = 0 (DSA treatment) and TEER from CTR measurement were set to 1 and each
measurement is expressed as a relative value. n (45 µg mL-1) = 5 wells from 2
cultures; n (400 µg mL-1) = 7 wells from 3 cultures, two-way ANOVA, ***p < 0.001,
**p < 0.01.
Next, a concentration-dependent impact of DSA on BBB integrity was probed. For
this purpose, cells were seeded in an ECIS 8-Well chamber and TEER was measured
continuously for up to 72 h after DSA application. The DSA concentration used in
the previously discussed experiments (45 µg mL-1) showed no significant impact on
the barrier integrity (n = 5 wells from 2 cultures, two-way ANOVA, P > 0.05) (Figure
15B), while high concentrations of DSA (400 µg mL-1) have a low reversible impact
on barrier integrity (Figure 17C). TEER values dropped to 79 % for G2-DSA (n = 7
wells from 3 cultures, two-way ANOVA, P < 0.01) and 73 % for G3-DSA (n = 7 wells
from 3 cultures, two-way ANOVA, P < 0.001) within the first 40 h. However, barrier
integrity recovered to 87 % for G2-DSA (n = 7 wells from 3 cultures, two-way
ANOVA, P > 0.05) and to 89 % for G3-DSA (n = 7 wells from 3 cultures, two-way
ANOVA, P > 0.05) at 72 h during DSA application. Additionally, Zona occludens 1
(ZO1) staining as marker of tight junctions also show maintenance of intact tight
monolayer in bEnd.3 cells treated for 24 h with DSA (45 µg mL-1) (Figure 18). Thus,
DSA represent a good biocompatible system which do not dramatically affect both
cell viability and BBB integrity.
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Figure 18. DSA effect on bEnd.3 monolayer. Representative epifluorescence
microscopy images from bEnd.3 cells culture treated with DSA (red) showing
maintenance of BBB integrity by tight junctions staining with zona occludens 1
marker (ZO1; green).
4.1.5 DSA uptake in astrocytes and neurons occurs without cytotoxic
effects
The aim for a successful brain treatment is not only to overcome the BBB, but also
to reach target cells. These target cells in CNS diseases might be neurons or
astrocytes. To investigate the potential of DSA to target NVU cells, primary cells
were treated for 24 h, fixed and co-stained with markers for astrocytes (GFAP) and
neurons (ß-III-tubulin). High rate of uptake could be observed for both generations
of DSA in glial cells (Figure 19A) which represent the cell type coming in close
contact with the tight layer of endothelial cells in BBB. In co-culture of neurons and
astrocytes, ß-III-tubulin stainings revealed uptake also in neuronal cells both in cell
body and in dendrites as shown by colocalization of NP-containing vesicles (Figure
19B).
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Figure 19.  DSA uptake in target cells. (A, B) Representative confocal tri-
dimensional orthogonal views of DSA (red) uptake in GFAP-positive primary
murine astrocytes (green) (A) and β-tubulin-positive primary murine neurons
(orange) (B).
As already observed for bEnd.3 cells, G3-DSA showed higher uptake properties than
G2-DSA in all NVU cells. In addition, these data confirmed the previously mentioned
hypothesis that lower G3-DSA transport values in triple co-culture system (Fig 11D)
may result from a high uptake in target cells located in the abluminal compartment.
For validation of nanoparticles for brain delivery it has to be taken into account that
delivery of exogenous molecules into the brain parenchyma might cause side
effects. Hence, in order to evaluate whether DSA affect cell viability of target cells,
the alamar blue assay for primary murine astrocytes and the TUNEL assay for
neurons were carried out, applying rising concentrations of DSA from 10 up to 400
µg mL-1. After 24 h treatment, alamar blue assay showed no changes in astrocyte
cell vitality for all analyzed concentrations, even for DSA concentration up to 400 µg
mL-1 (n > 9 from 3 cultures, one-way ANOVA, P > 0.05) and significant differences
were observed in comparison with a cytotoxic staurosporine treatment (live: 100.34
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± 1.4 % vs. dead: 0.5 ± 0.49 %, n > 9 from 3 cultures, one-way ANOVA, P < 0.05)
(Figure 20A). Comparable results were obtained for primary neuronal cultures by
TUNEL assay. There was no significant increase in apoptotic rate for DSA treated
neurons (n > 9 from 3 cultures, one-way ANOVA, P > 0.05) (Figure 20B), but a
significant increase could be observed for the dead control treated with
staurosporine (live: 1 ± 0.03 vs. dead: 2.3 ± 0.14, n > 9 from 3 cultures, one-way
ANOVA, P < 0.05). These data revealed the ability of DSA to penetrate the NVU cells
without induced cytotoxic effects.
Figure 20.  DSA cytotoxicity in target cells. (A, B) Cell vitality after DSA treatment
(24 h) in primary murine astrocytes quantified by Alamar Blue assay (A) or in
primary murine neurons by Fluorometric TUNEL assay (B). Positive control (dead):
cell toxin staurosporine. primary murine  astrocytes: n > 9 from 3 cultures; primary
murine neurons: n > 9 wells from 3 cultures; one-way ANOVA; ***p < 0.001.
4.1.6 DSA are transported to the brain and taken up by NVU cells in vivo
Uptake and transport assays in vitro proved that G3-DSA is more promising for
further applications since the higher uptake in cells suggests higher efficiency in
penetrating endothelial cells, crossing the BBB and more easily reaching target cells.
For this reason, in vivo studies were focused on G3-DSA to reach CNS after tail
intravenous injection in mice. Coronal slices of 30 µm from brains isolated by CTR
or Cy5-labeled-G3-DSA treated mice were carefully analyzed and screened for DSA
specific signal.
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Three main barrier layers are considered to separate the blood and the CNS: the
endothelium of the brain microvessels, the epithelium of the choroid plexus, and
the epithelium of the arachnoid mater (Abbott 2014). Uptake of G3-DSA was easily
detectable in cells surrounding blood vessels (Figure 21A).
Figure 21.  In vivo G3-DSA brain transport in mice. (A-D) Representative confocal
images of G3-DSA (white) uptake at blood-brain barriers and periventricular area
24 hours after intravenous injection (450 µg mL-1 blood). (E) Streptavidin
immunoblotting of brain lysate from CTR and 2 x G3-DSA treated mice (450 µg mL-
1) 24 h post intravenous injection.
G3-DSA were also clearly taken up in meninges in correspondence of the second
barrier layer represented by the epithelium of the arachnoid mater (Figure 21B).
However, highest uptake was observed in choroid plexus and ventricles, suggesting
that G3-DSA were released into the cerebrospinal fluid as well (Figure 21C, D). These
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three barriers represent the ways our nanocarriers can take to the brain. Uptake of
G3-DSA into the brain was also confirmed by WB analysis on brain lysate. On PVDF
membrane, clear bands for DSA were visible after detection of streptavidin core
(Figure 21E). To more specifically identify the localization of nanocarriers within the
brain tissue, G3-DSA signal was detected in combination with staining for
endothelial cells using the marker endoglin (CD105), glia using the marker glial
fibrillary acidic protein (GFAP), or neurons using the marker NeuN. CD105 staining
clearly showed G3-DSA uptake on the lumen side of the vessels as well as in the
abluminal brain parenchyma (Figure 22A). Lower intensity DSA signals were
detected also in target cells: astrocytes (Figure 22B) and neurons (Figure 22C).
56
Figure 22.  In vivo G3-DSA uptake in NVU cells in mice. (A-C) Representative
confocal images of G3-DSA (white) uptake in brain endothelial cells (CD105; green)
(A), astrocytes (GFAP; green) (B) and neurons (NeuN; green) (C) 24 h after
intravenous injection (900 µg mL-1).
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4.1.7 DSA reach also peripheral organs in vivo after intravenous injection
Although this study aims to investigate DSA transport to the brain, additionally the
uptake of G3-DSA in other organs was investigated. Therefore, after each NP
application, kidney, liver, spleen, lung and heart were also collected and screened
for NPs uptake. NPs signal was detected in spleen, lung and heart with low uptake
rates (Figure 23A, B, C). However, G3-DSA showed high uptake rates in kidney and
liver (Figure 23D, E).
Figure 23.  In vivo G3-DSA biodistribution in mice. (A-E) G3-DSA (white) uptake in
different organs (kidney (D), liver (E), lung (A), spleen (B), heart (C)) 24 h after
intravenous injection (450 µg mL-1).
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The present data demonstrate high kidney uptake of DSA, which could indicate a
high rate of clearance or renal reabsorption. To further investigate the case for DSA,
WB analysis on blood samples collected 24 h after G3-DSA treatment revealed a
circulation of the nanocompound indicating that NPs were still available for uptake
(Figure 24).
 Figure 24.  G3-DSA permanence in blood
after 24 h from iv. application in mice.
Streptavidin immunoblotting of blood
samples from CTR and G3-DSA treated mice
(450 µg mL-1) 24 h post intravenous injection.
On PVDF membrane several not specific
bands are detectable due to the presence of
endogenous antibodies in blood samples.
Arrow head: specific band for G3-DSA.
4.1.8 DSA do not affect BBB integrity in vivo
To assess the use of DSA for medical applications, the BBB integrity was studied by
the use of intravital dyes (tracers, markers) of molecular weight greater than 180
Da, which preclude passage across an intact barrier. Evans blue (EB) (MW 961 Da)
is one of the largest dyes, which in blood binds to the albumin fraction (EBA) to give
rise to a high-molecular complex (EBA = 68,500 Da) (Kozler and Pokorný 2003). EB
was intravenously injected 3 h before the end of DSA treatment to assess BBB
integrity. The analysis of the brains did not show macroscopically EB infiltration in
brain tissue related to DSA treatment (Figure 25A). Epifluorescence microscopy
revealed a localized EB fluorescence in blood vessels without extravasation of the
dye in both Sham and G3-treated animals (Figure 25B). In addition, analysis of brain
lysate did not show significant change of EB fluorescence compared to the sham
animal measuring the µg of EB g-1   of brain tissue (Sham: 0.17 ± 0.03 µg g-1 of brain
tissue vs. G3-DSA: 0.19 ± 0.02 µg g-1 of brain tissue, n = 3 brain lysates from 3 mice,
Mann-Whitney U test, P = 0.6905) (Figure 25C). This data exclude a correlation
between in vivo G3-DSA uptake and BBB disruption and proves the biocompatibility
of our protein nanocarriers.
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Figure 25.  In vivo G3-DSA effect on BBB integrity in mice. (A) Representative
pictures of intact brains showing absence of Evans Blue (EB) extravasation in sham
as well as G3-DSA-treated mice after 24 h from the injection. (B) Representative
epifluorescence microscopy images from brain slices showing presence of EB (red)
in blood vessels without permeation in brain parenchyma in sham and G3-DSA-
treated mice. (C) EB quantification in brain lysate from sham and G3-DSA-treated
mice. Data are expressed as µg of EB per g of brain tissue. n = 3 brain lysates from
3 mice; Mann-Whitney U test; ns = not significant.
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4.2       Fluorescent Nanodiamonds as nanotheranostics platform for brain drug delivery via
crossing an intact BBB
4.2.1 dcHSA-fNDs are taken up by brain endothelial cells in vitro
To assess the transport of dcHSA-fNDs into the brain, at first in vitro studies were
carried out in order to understand whether the investigated nanocompound was
able to penetrate the first cell layer composing the BBB: the endothelium of the
microvessels.
bEnd.3 cells as brain endothelial cell lines were screened for dcHSA-fNDs-
rhodamine signal by confocal microscopy after 24 h of dcHSA-fNDs treatment.
Orthogonal view and 3D-reconstruction from deconvolved z-stacks showed dcHSA-
fNDs fluorescence in the cell cytosol as dcHSA-fNDs-containing-vesicles (Figure 26).
Figure 26.  dcHSA-fNDs uptake in bEnd.3. (A-B) Representative confocal
orthogonal view (A)  and 3D-reconstruction of dcHSA-fNDs (red) uptake (B); cell
nuclei were stained with DAPI; scale bar = 5 µm
Additionally, a comparison carried out on the different signals obtainable from
dcHSA-fNDs (internal reflection fluorescence, inner fluorescence and shell
fluorescence) demonstrated that reflection, bodipy488-labeled-dcHSA-shell and NV
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signals were all detectable and colocalizing (Figure 27) demonstrating the
maintenance of integrity and inner properties in the biological environment.
Figure 27.  dcHSA-fNDs detectable colocalizing signals.  Representative confocal
picture of reflection (magenta), NV (red), dcHSA-shell (green) signals for dcHSA-
fNDs in bEnd.3 cells; scale bar = 20 µm.
Additionally, bEnd.3 cells were treated for 24 h with dcHSA-fNDs in combination
with FITC-transferrin (TF) or the B subunit of cholera toxin-alexa-488 (CTX) to
identify the endocytosis mechanism. dcHSA-fNDs colocalized for 27.7 ± 3.07 % with
TF and 70.55 ± 3.9 % with CTX showing a significantly higher preference for
caveolae-mediated endocytosis (TF vs CTX: n = 12 regions of interest from 3
cultures, Mann-Whitney U test, P < 0.0001) (Figure 28A,B).
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Figure 28.  dcHSA-fNDs uptake mechanism in bEnd.3. (A) Representative confocal
orthogonal view and 3D-reconstruction of dcHSA-fNDs colocalization with CTX or
TF (green); scale bar = 5 µm. (B) Percentage of colocalizing dcHSA-fNDs-containing-
vesicles with CTX or TF –containing vesicles; n = 12 ROIs from 3 cultures, Mann-
Whitney U test, ***p < 0.001.
63
4.2.2 dcHSA-fNDs are transported across BBB in vitro in a size-independent
manner
In order to investigate the ability of dcHSA-fNDs to cross the BBB we used an in vitro
model composed by bEnd.3 cells as endothelial cell line seeded on the luminal side
of a transwell insert. 30 µg mL-1 of 40 nm or 60 nm dcHSA-fNDs were applied in
luminal compartment of the transwell BBB model in order to assess their ability to
be transported from one side to the other and whether the size contributes
considerably to the migration process. After 24 h treatment dcHSA-fNDs
fluorescence was measured in collected abluminal medium to estimate the
transport rate. The percentage of transport was 45.17 ± 7 % (n = 6 wells from 3
cultures) for 40 nm dcHSA-fNDs and 38.6 ± 7.6 % (n = 6 wells from 3 cultures) for 60
nm dcHSA-fNDs compared to the 100 % (100 % dcHSA-fNDs 40nm: 100 ± 5.4 %; 100
% dcHSA-fNDs 60nm: 100 ± 3 %; n > 6 wells from 3 cultures) of transport with no
significant size dependent difference (one-way ANOVA, P < 0.0001) (Figure 29A).
The data indicate that dcHSA-fNDs are capable to efficiently cross BBB in vitro. Size-
independent transport is the reason why further experiments have been carried out
using a mixture of 40-60 nm dcHSA-fNDs for which transport efficiency was
additionally confirmed as shown in Figure 29B. The choice of a size mixture referred
also to the preference of reducing purification steps in order to simplify the dcHSA-
fNDs production process decreasing the possible impact of purification reagents on
biocompatibility and the time of synthesis.
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Figure 29.  dcHSA-fNDs transport across BBB in vitro. A) Mean relative transport
for 40 nm or 60 nm dcHSA-fNDs (A) or 40-60 mixture dcHSA-fNDs (B) across bEnd.3
cells monolayer. At time = 0 h of transport assay dcHSA-fNDs were applied at a
concentration of 30 µg mL-1 for 24 h. Abluminal fluorescence is expressed as
relative values compared to the 100 % of dcHSA-fNDs transport in inserts without
cells (100% dcHSA-fNDs); n ≥ 6 wells from 3 cultures, one-way ANOVA, ***p <
0.001, ns = not significant.
4.2.3 dcHSA-fNDs transport employs transcytosis involving endosomal
localization
The initial intracellular pathway of a vesicle upon internalization is the same
whether it is internalized via clathrin-mediated or caveolae-mediated endocytosis
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and begins with the early endosomes (EE). Without selective retrieval, the material
located in EE mostly will be delivered to late endosomes (LE) and lysosomes. In
order to understand whether dcHSA-fNDs were located in EE or LE/lysosomes,
bEnd.3 cells were fixed after 24 h of treatment and using immunocytochemistry, EE
and LE were stained. Orthogonal view from z-stacks obtained by confocal
microscopy revealed dcHSA-fNDs-containing-vesicles localizing with EE and
LE/lysosomes (Figure 30A).
Figure 30.  dcHSA-fNDs endosomal compartments localization in bEnd.3 cells. (A)
Representative confocal orthogonal view and 3D-reconstruction of dcHSA-fNDs
(red) colocalization with EE or LE/lysosome (green); scale bar = 7 µm. (B)
Quantification of colocalization for dcHSA-fNDs-containing vesicles with early
endosomes or late endosomes; n = 12 ROIs from 3 cultures, Mann-Whitney U test,
***p < 0.001.
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Quantitative analysis showed a colocalization of 2.4 ± 0.5 % with EE and 15.14 ± 4.15
% with LE/lysosomes (n = 12 regions of interest from 3 cultures, Mann-Whitney U
test, P < 0.0001) (Figure 30B). Concerning the intracellular fate of dcHSA-fNDs
another possibility would have been the induction of autophagy with subsequent
internalization of dcHSA-fNDs in autophagosomes. Therefore, dcHSA-fNDs signal
was detected in combination with staining for autophagosomes using LC3.
Representative orthogonal z-stacks showed LC3-positive vesicles in both CTR and
dcHSA-fNDs treated cultures (Figure 31A). Indeed, it was already described in
literature that endothelial cells show high basal autophagy. Very few dcHSA-fNDs-
containing vesicles might be identified as autophagosomes. This assumption was
clearly confirmed by quantification of colocalization rate of dcHSA-fNDs signal with
LC3 signal. dcHSA-fNDs colocalize with a percentage of 0.98 ± 0.52 % (n = 10 regions
of interest from 3 cultures) with LC3-positive-vesicles that represents a negligible
value considering the high rate of basal autophagy (Figure 31B).
Figure 31. dcHSA-fNDs autophagosomal localization in bEnd.3 cells. (A)
Representative confocal orthogonal view of dcHSA-fNDs (red) colocalization with
LC3 (green); scale bar = 5 µm. (B) Percentage of colocalizing dcHSA-fNDs with LC3;
n = 10 ROIs from 3 cultures.
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Taken together this data suggest intracellular trafficking involving endosomes that
lead to transcytosis of dcHSA-fNDs from luminal to abluminal side with no
involvement and induction of autophagy mechanisms.
4.2.4 dcHSA-fNDs are taken up by astrocytes and neurons in vitro
After transcytosis dcHSA-fNDs reach the abluminal compartment. In physiological
condition after moving from the lumen of the blood vessel to the abluminal brain
parenchyma, dcHSA-fNDs will get in contact with other cell types: mostly neurons
and astrocytes. In order to assess the ability of dcHSA-fNDs to be delivered to
neurons and astrocytes, we studied whether dcHSA-fNDs were taken up by target
cells using immunocytochemistry on murine primary cultures. Astrocytes were
stained with marker glial fibrillary acidic protein (GFAP) while neurons with the
marker NeuN to visualize the cell body or β-III-tubulin for axons and dendrites.
Orthogonal view from z-stacks of dcHSA-fNDs-treated-astrocytes showed high
uptake predominantly in the perinuclear region (Figure 32A). However, in neurons,
confocal microscopy revealed higher localization of dcHSA-fNDs in axons and
dendrites as visible in β-III-tubulin staining than in perinuclear region as visible in
NeuN staining (Figure 32B).
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Figure 32.  dcHSA-fNDs uptake in primary murine neurons and astrocytes in vitro.
(A) Representative confocal orthogonal views of dcHSA-fNDs (red) uptake in
astrocytes by GFAP marker (green) and perinuclear localization. (B) Neuronal
uptake of dcHSA-fNDs in cell body stained by NeuN (magenta) and dendrites and
axons stained by β-tubulin (green); scale bar = 5 µm.
4.2.5 dcHSA-fNDs show direct cell-cell migration mediated by actin bridges
The analysis of the dcHSA-fNDs uptake and localization pointed out that although
many NPs-containing vesicles were localized in the perinuclear area especially in
bEnd.3 cells and astrocytes, there was also a consistent distal localization that
brought us to carry out further investigations. At first, rhodamine-phalloidin was used
to stain bEnd.3 cells cytoskeleton in order to identify in which cell area distal
localization was occurring. Intriguingly, dcHSA-fNDs-vesicles located in a cell
structure connecting two adjacent cells (Figure 33). The identified actin bridges have
been characterized as tunneling nanotubes (TNT) already observed in many cell types
in vitro and in developing embryos of different species in vivo, representing thin
membranous bridges connecting cells over long distances and transferring various
cellular components from cell to cell (Gerdes, Rustom and Wang 2013).
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Figure 33. dcHSA-fNDs localization in actin bridges in bEnd.3 cells. Representative
confocal orthogonal view of dcHSA-fNDs (green) localization in phalloidin-labeled-
actin (magenta) bridges in bEnd.3 cells. White arrows indicate TNTs-colocalizing-
particles. Scale bar = 20 µm.
Live cell imaging and time lapse have been carried out on bEnd.3 cells in order to
have a closer view on the mechanism of direct cell-cell transport of dcHSA-fNDs along
TNTs. Due to high contrast of dcHSA-fNDs in brightfield it was possible to observe
dcHSA-fNDs-vesicles moving in TNTs (Figure 34). Fluorescent signal from dcHSA-fNDs
made possible to ascribe the brightfield signal to dcHSA-fNDs. Additionally,
combining fluorescence at time = 0 min, fluorescence at time = 45 min and brightfield
picture at time = 0 allowed us to compare movements of different vesicles located in
different positions along the same TNT (Figure 34). The data obtained by the time-
lapse revealed a unidirectional migration from an initiating cell to a target cell and a
faster movement while getting closer to the target cell (Figure 34; white arrows).
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Figure 34. dcHSA-fNDs migration along TNTs in bEnd.3 cells .  Time-lapse showing
dcHSA-fNDs movements along TNTs in bEnd.3 cells within 45 min via merge of BF
picture with fluorescence at time 0 min (red) and time 45 min (green). White
circles indicate the dcHSA-fNDs taken into consideration; white arrows indicate
length and direction of dcHSA-fNDs migration. Scale bar = 20 µm.
Previously published studies have also demonstrated TNT formation occurring in
neurons and astrocytes in mono-culture as well as in co-cultures (Gerdes et al. 2013,
Sun et al. 2012, Tardivel et al. 2016). Indeed, live cell imaging and time lapse on co-
cultures of immature neurons/glia showed dcHSA-fNDs-vesicles in comparable
structures to the ones observed for bEnd.3 cells (Figure 35A). GFAP/ß-III-
tubulin/rhodamine-phalloidin costainings revealed also TNTs connecting astrocytes
and neurons (Figure 35B). Interestingly, these data strongly support the hypothesis
of direct transfer of dcHSA-fNDs observable for all NVU investigated cells.
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Figure 35.  dcHSA-fNDs localization in actin bridges in neurons/glia co-cultures.
(A) Representative time lapse of dcHSA-fNDs movement along TNTs in neurons.
Dashed lines indicate the edges of dcHSA-fNDs-containg vesicle movement. (B)
Representative confocal orthogonal view of dcHSA-fNDs (white) colocalization
with TNTs (white arrows) observable via phalloidin staining (magenta) and cellular
specific markers: GFAP for astrocytes (red) and ß-III-tubulin for neurons (green).
Scale bar = 20 µm
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4.2.6 dcHSA-fNDs do not affect cell vitality and BBB integrity in vitro
Effect on bEnd.3 cells monolayer and on astrocytes and neurons viability was
carefully investigated. In order to monitor the bEnd.3 cells monolayer integrity,
using CellZscope, TEER was constantly measured during the dcHSA-fNDs treatment
in transwell inserts. The TEER dropped slightly for both CTR and dcHSA-fNDs-treated
inserts while during the whole time of the treatment no difference between CTR
and dcHSA-fNDs-treated samples could be observed (n = 6 wells from 3 cultures,
two-way ANOVA, P > 0.05) (Figure 36A, B). For experiments carried out on mixture
40-60 nm dcHSA-fNDs, for treated cells TEER measurement showed a slight increase
in TEER values compared to untreated samples (n = 6 wells from 3 cultures, two-
way ANOVA, P > 0.05) (Figure 36B). In addition, to assess cell vitality in astrocytes
and neurons, Alamar blue assays have been carried out applying rising
concentrations (0.5, 10 or 30 µg mL-1) of dcHSA-fNDs or dcHSA. This experimental
design was established to be able to investigate the contribution of the HSA-based
coating in case of toxicity. Naked-NDs could not be used to assess cell vitality due
to the tendency to aggregate. Indeed, as already described in the introduction
(1.5.1), the dcHSA is responsible for the NDs colloidal stability. The results showed
no significant change in cell vitality of both astrocytes (n > 7 wells from 3 cultures,
one-way ANOVA) (Figure 36C) and neurons (n > 7 wells from 3 cultures, one-way
ANOVA) (Figure 36D) for all investigated concentrations and treatments. On the
contrary, staurosporine positive control treatment resulted in a significant decrease
in cell vitality compared to CTR (n > 7 wells from 3 cultures, one-way ANOVA, P <
0.0001) (Figure 36C, D). These data suggest that dcHSA-fNDs do not have evident
toxic effects on investigated cells.
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Figure 36.  dcHSA-fNDs effect on BBB integrity and cell viability. (A, B) On bEnd.3
cell monolayer BBB in vitro integrity investigated for the duration of the treatment
(24 h) with dcHSA-fNDs 40 nm, 60 nm (A) or dcHSA-fNDs mixture 40-60 nm (B).
TEER was measured by CellZscope and the values at t = 0 were set to 100 % and
each following measurement was expressed in relative percentage; n = 6 wells
from 3 cultures. (C, D) Cell vitality after different concentration of dcHSA or dcHSA-
fNDs treatment (24 hr) in primary murine astrocytes (C) or in primary murine
neurons (D) quantified by Alamar Blue assay. Positive control: cell toxin
staurosporine. Astrocytes: n > 7 from 3 cultures; neurons: n > 7 wells from 3
cultures; one-way ANOVA; ***p < 0.001.
4.2.7   dcHSA-fNDs cross the BBB and reach the brain after intravenous injection
in mice
The in vitro data highlighted the potential ability of dcHSA-fNDs to cross the BBB.
Next, in order to envision a possible clinical application, we investigated whether
dcHSA-fNDs were able to reach the brain after tail vein injection in mice. After 24 h
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from the application (500 µg mL-1 of blood of dcHSA-fNDs), 30 µm slices from brain
and liver were screened for dcHSA-fNDs signals. Since previous biodistributional
studies have demonstrated that cationic NPs are higly taken up by liver, liver slices
were used as positive control for injection efficiency (Blanco, Shen and Ferrari
2015).  dcHSA-fNDs signals were clearly visible in liver slices allowing us to
additionally compare the different dcHSA-fNDs signals (reflection, bodipy488-
labeled-dcHSA-shell, NV) intensity in tissue (Figure 37). The high tissue
autofluorescence strongly affected clear detection for fluorescence signals, thus,
reflection resulted in the most efficient detection system presenting high signal to
noise ratio.
Figure 37.  dcHSA-fNDs uptake in liver in vivo.  Representative confocal picture of
reflection (white), NV (red), dcHSA-shell (green) signals for dcHSA-fNDs in liver;
scale bar = 20 µm.
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According to this evidence, brain slices were carefully screened for dcHSA-fNDs
reflection signals. Orthogonal view of confocal z-stacks showed dcHSA-fNDs in brain
slices (Figure 38A). Astrocytes and neuronal cell bodies were stained respectively
for GFAP and NeuN, thus it was possible to better characterize the brain uptake and
identify the dcHSA-fNDs-positive cells. dcHSA-fNDs were clearly detectable close at
the BBB site and some NPs-containing-vesicles colocalized with GFAP-positive-
astrocytes surrounding vessels or NeuN-positive neurons as observable from 3D-
reconstructions (Figure 38B, C). Thus, these data clearly confirmed the ability of
dcHSA-fNDs to cross the BBB and reach the brain parenchyma in vivo.
Figure 38. dcHSA- fNDs transport across the BBB and uptake in neurons and
astrocytes in vivo. (A) Representative confocal orthogonal views of dcHSA-fNDs
(white) signals in brain slices. (B, C) Representative confocal orthogonal view of
dcHSA-fNDs (white) localization in GFAP-positive astrocytes (green) (B) and NeuN-
positive neurons (green) (C); white arrows indicate area of clear dcHSA-fNDs
uptake; scale bar = 40 µm.
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5. Discussion
Neurological disorders have high social impact due to severe morbidity and mortality.
Although many therapeutic targets and suitable drugs have already been identified and
characterized, the BBB, a very tight and unassailable biological barrier, prevents them from
reaching the CNS. The current approaches for neurological disease treatments make use of
very limited or invasive methods. Therefore, the development of non-invasive, biocompatible
and efficient new brain drug delivery systems is eagerly needed.
A high variety of NP-based systems has been investigated to achieve a successful treatment
of CNS diseases such as Poly(n-butylcyanoacrylate)-NPs, Methoxypoly(ethylene glycol)-
polylactide or Poly(lactide-co-glycolide), liposomes and many inorganic compounds (quantum
rods, mesoporous silica NPs) mostly functionalized with BBB-targeting molecules. However,
all these nanosystems have shown still limited potential for clinical application mainly due to
inefficient pharmacological effects and limited capabilities for drug loading, safety and
bioavailability of the encapsulated drug (Grabrucker et al. 2013). According to the need of
providing still new strategies for successful clinical implementation of nanomedicine, in this
doctoral thesis two different nanosystems have been characterized and studied for brain
targeting: dendronized streptavidin (DSA) and dcHSA-fluorescent nanodiamonds (dcHSA-
fNDs).
5.1 Dendronized streptavidin represents a promising nanoplatform for brain drug
delivery
In the first part of this study a customized, non-invasive hybrid nanocarrier system (DSA)
suitable for transporting therapeutic agents into CNS via systemically intravenous
administration is presented. DSA are composed by a tetrameric streptavidin core linked to
second or third generation PAMAM dendrimers. The nanosystems provided kindly by Dr.
David Ng from the laboratory of Prof. Tanja Weil at the Max Planck Institute for polymer
research in Mainz, have a size of 5 nm and are positively charged (positive charges: 28 for G2-
DSA and 60 for G3-DSA). In a previous study, Ng and colleagues successfully demonstrated
that the “bio-click” self-assembly of dendrons and therapeutics on a streptavidin adapter
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supplies a supramolecular complex with high stability and simple possibility of
functionalization (Ng et al. 2013).
The first question that has been addressed in this thesis is whether DSA are taken up by NVU
cells. Initially, the brain endothelial cells as first cell layer DSA have to penetrate in order to
reach the brain via crossing the BBB were studied. bEnd.3 cell uptake was observable by
fluorocytochemistry as well as via western blot (Figure 9). Combining microscopy and
biochemistry data provides a not trivial advantage. Indeed, direct detection of the NP core
independent of fluorescent labels excludes false positive data by free fluorescent-dye.
Furthermore, a degradation of the detected protein core within 24 h could be excluded. The
uptake results point out an important fact. Indeed, the data indicate that differences in the
structures and in the amount of positive charges of the dendrimers trigger the ability of DSA
to penetrate brain endothelial cells with a more pronounced uptake for G3-DSA than for G2-
DSA. It is assumable that the cell uptake is facilitated by the amount of positive charges
because of their interaction with the negative charges of the cell membrane as driving force
for cell penetration. Additionally, although previous studies demonstrated that PAMAM
dendrimers follow a clathrin-mediated endocytosis in HeLa cells (Albertazzi et al. 2010), in
contrast to this, co-uptake results show that, the DSA in bEnd.3 cells do not follow only the
clathrin-mediated but also and with higher percentage a caveolae-mediated pathway, which
is the most common uptake mechanism in endothelial cells (Voigt et al. 2014, Hillaireau and
Couvreur 2009, Frank et al. 2003) (Figure 10), indicating that the PAMAM dendrimer hybrids
acquire different uptake properties compared to dendrimers alone. DSA uptake was also
demonstrated in the other investigated NVU cells: primary murine astrocytes and neurons
(Figure 19). Thus, DSA are able to penetrate all the NVU cells showing the ability of potentially
crossing the endothelial layer and reaching brain target cells (astrocytes and neurons).
Subsequently, transport was addressed in two different in vitro BBB models: a porcine model
composed of a monolayer of primary porcine brain endothelial cells (PBECs) and a murine
triple co-culture employing bEnd.3 cells as brain endothelial cell line, primary murine
astrocytes and primary murine neurons. The advantage of primary cells is that they keep
features cell lines might have lost, like expression of efflux transporters and brain capillary
specific enzymes important for the physiological function of the BBB. The porcine model was
selected to obtain high transendothelial electrical resistance (TEER) values without the need
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of co-culturing with astrocytes. Additionally, porcine genome, physiology and anatomy reflect
best the human biology compared to other laboratory animals (Patabendige et al. 2013b,
Patabendige et al. 2013a). On the other hand, since astrocytes and neurons are mainly
responsible for the specialization of brain endothelial cells, the triple-co-culture system
represents the best in vitro approach to model the BBB  (Ruck, Bittner and Meuth 2015).
The obtained results showed that in both in vitro BBB systems, high transport efficiency for
G2-DSA and G3-DSA from the luminal to the abluminal compartment could be observed
(Figure 11).  Comparing DSA transport rate (in the range from 16 to 38 %) with previously
published in vitro transport rates for other nanosystems highlights strongly the great potential
of DSA to efficiently target the brain. However, the comparison has to be carefully addressed
due to different used experimental settings (e.g., the species of cells used, mono- and co-
cultures models). Indeed, using BBB models with low TEER (higher passive diffusion) we have
to expect higher transport rates (Liu et al. 2014) as well as for nanosystems employing specific
brain-targeting ligands (Clark and Davis 2015). DSA show in general a percentage of transport
higher compared to transport of gold-NP (conjugated to therapeutic agent and brain-targeted
peptide), transferrin receptor-targeted immunoliposomes and neutral, anionic, and cationic
malto-dextrin 60 nm nanoparticles  (transport rates in a range from 0.4 to 14 %) (Fenart et al.
1999, Johnsen et al. 2017, Prades et al. 2012). Thus, the high in vitro transport efficiency for
DSA reveals promising brain-targeting properties of the investigated PAMAM dendrimer-
bioconjugates.
In triple co-culture a significant higher luminal transported fraction for G2-DSA (Figure 11D)
compared to G3-DSA was observable. Interpreting these results, it has to be considered that
quantification of NPs in the media did not take into account NPs taken up by NVU cells in the
abluminal compartment also involved in the uptake of DSA as clearly shown in the uptake
experiments in astrocytes and neurons (Figure 19). Therefore, an underestimation of the real
transport rate is expected since the total transport of DSA is constituted by DSA in abluminal
medium + DSA taken up from cells seeded at the bottom of the abluminal compartment. The
used method measured the DSA fluorescence in the abluminal medium that represent only
one component of the total transport. Intriguingly, further determination of estimated DSA
fraction incorporated in cells (estimated DSA cellular fraction = DSA initial fluorescence - DSA
abluminal fluorescence - DSA luminal fluorescence) (gray bar; Figure 12) revealed that for G3-
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DSA in the triple co-culture model a considerably higher fraction of fluorescence than mono-
culture vanished from the luminal and abluminal compartments (Figure 12), while for G2-DSA
the loss of fluorescence was constant and comparable between the two investigated BBB
models (Figure 12). Indirectly, these results strongly suggest that a higher fraction of G3-DSA
than G2-DSA is taken up by cells in triple co-culture compared to mono-culture.
To validate the used in vitro transwell systems as suitable model to study the transport, TEER
was monitored and as additional parameter, since the tight junctions restrict the paracellular
diffusion of hydrophilic tracers (Gaillard and de Boer 2000), the apparent permeability
coefficient (Papp) for FITC-dextran 4 KDa was also measured. TEER and Papp measurements
assured that the shown efficiency of DSA to cross BBB in vitro is not related to relevant
paracellular transport (Figure 11F, G).
Uptake and transport results suggest transcytosis. Therefore, intracellular trafficking was
deeper investigated and DSA were found to localize in both early (EE) and late (LE) endosomes
with a very pronounced colocalization percentage for EE (Figure 13). Indeed, the initial
intracellular trafficking of a vesicle upon internalization begins with EE. For G2-DSA higher EE
colocalization than G3-DSA was observed. The short trafficking time in EE for G3-DSA might
be responsible for high uptake and transport rates.  Additionally, blocking the endosomes-
lysosomes fusion, no lysosome-mediated short term degradation of DSA was observed (Figure
16).
These data, combined with the evidence of low localization in late endosomes (Figure 13C),
suggest the involvement of a “proton-sponge” mechanism as already proposed in previous
studies for PAMAM dendrimers (Wanling and KW 2012), which describes that cationic
polymers have pH-buffering properties inducing endosomal disruption. For this reason,
PAMAM dendrimers exhibit high transfection efficiency compared to compounds without
buffering ability (Zhou et al. 2006, Zhou et al. 2007). This fact offers the additional possibility
of using DSA as a promising nanocarrier for nucleic acid and siRNA delivery preventing
lysosomal degradation, one of the limiting steps for successful nucleic acid efficiency.
Thus, many DSA were localized in endosomes but still, looking at the percentage of
colocalization we were able to identify the 84 % of intracellular compartment for G2-DSA and
48 % for G3-DSA. In order to identify the remaining intracellular compartment sequestering
DSA, we studied the colocalization with other intracellular compartments markers (VAMP3 for
80
recycling endosomes, TfR for transferrin receptor, LC3 for autophagosomes). Colocalization
with the other investigated intracellular compartments was not observable despite few DSA-
containing vesicles localizing with LC3-positive-autophagosomes (Figure 15). Therefore,
autophagosomal localization required some further investigation in order to exclude induction
of autophagy as sensor of induced cellular stress (Cherra and Chu 2008, Codogno and Meijer
2005). Combining immunocytochemistry and western blot analysis, no induction of autophagy
was observed (Figure 15). Thus, since endothelial cells show a relatively high basal autophagy
(Urbanek et al. 2014), the detection of few NPs-containing-autophagosomes suggests that
DSA, in particular G3-DSA given the high rate of uptake, might also be incorporated in
autophagosomes during basal autophagy. The study of autophagy induction as toxicity
parameter relates to another important question to be addressed: are DSA biocompatible?
Therefore, cell vitality and barrier integrity to study the biocompatibility of DSA in vitro were
analyzed. DSA did not show any effects on cell vitality of NVU cells up to concentration of 400
µg mL-1 (Figure 17A; 20). This finding was extremely important due to the fact that cationic
PAMAM dendrimers have been often associated to high cytotoxicity (Jain et al. 2010). For
example, Jevprasesphant and colleagues have carried out a meticulous study aiming to
correlate dendrimer generation to cell viability. They have found that although G2-PAMAM
dendrimers do not affect cell viability also at relatively high concentration, G3-PAMAM induce
severe cell viability decrease (Jevprasesphant et al. 2003). On the contrary, the results
presented in this thesis revealed that the use of a streptavidin core provides an elegant
approach towards synthesis and biocompatibility. Simultaneously, experiments on BBB
integrity showed maintenance of TEER stability over treatment time at a concentration of 45
µg mL-1 and a slight temporary decrease in TEER at 400 µg mL-1 of maximal 27 % (Figure 17B,
C). In agreement with previous studies and established therapies, this is a mild transient
paracellular opening of BBB without destroying the NVU (Hülper et al. 2013), which does not
have to be considered strictly as a deleterious event but even as a system to better deliver
molecules to the CNS (Choi et al. 2008).
The in vitro studies showed the potential of DSA to cross the BBB, target neuronal cells and
therefore potentially act as delivery system in clinical applications. The in vitro data presented
so far demonstrated the importance of the dendrimer shell in promoting uptake and
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transport, which is dependent on the dendrimer-generation most likely due to the amount of
positive-charges. The in vitro approach enables to evaluate effects and interactions of DSA on
each cell type, to investigate cytotoxicity and to look in depth to mechanism of intracellular
trafficking. On the other hand, in vivo behaviour of nanocarriers is unpredictable due to the
interaction with blood components which might induce changes in the nature of the
nanocarriers before reaching their target. Therefore, in vivo studies are essential to prove the
suitability of a candidate compound for nanomedicine applications.
Uptake and transport assays in vitro proved that G3-DSA is more promising for further
applications since the higher uptake in cells suggests higher efficiency in penetrating
endothelial cells, crossing the BBB and more easily reaching target cells. For this reason, we
focused the study on G3-DSA to reach CNS after tail intravenous injection in mice.
In vivo experiments performed with G3-DSA showed uptake and transport at the BBBs site
predominantly in ventricles and choroid plexus (Figure 21). Three main barrier layers are
considered to separate the blood and the CNS: the endothelium of the brain microvessels, the
epithelium of the choroid plexus, and the epithelium of the arachnoid mater (Abbott 2014).
Therefore, it is not surprising that G3-DSA were more easily detectable in areas surrounding
the ventricles as consequence of the high uptake in that specific brain area (Figure 21D). G3-
DSA were detectable in investigated NVU cells with higher intensity signals close to brain
endothelial cells than in astrocytes and neurons (Figure 22A). Indeed, the CD105 staining for
brain endothelial cells showed clearly G3-DSA signal localized on the abluminal side of the
blood vessels (Figure 22A). These results indicate an effective migration of nanocarriers from
blood to brain which might follow the hypothesis of permeation from endothelial cells to
neurons mediated by astrocytes whose endfeet take up DSA by surrounding the endothelium
of blood vessels (Figure 39). A comparable mechanism might be responsible for the migration
of pure PAMAM dendrimers through the corpus callosum 1-week post intracranial injection
described by Srinageshwar and colleagues (Srinageshwar et al. 2017).
Additionally, by quantification of G3-DSA fluorescence in brain lysates, it was possible to
determine the % of injected dose (% ID) in the brain with 0.03 ± 0.0 % and an average
concentration of 0.44 ± 0.03 µg/g brain after iv injection of 60 mg/kg cy5-G3-DSA. The
obtained values of  G3-DSA in the brain are in the range of known dendrimer systems (Ke et
al. 2009, Nance et al. 2016) showing a 10-fold higher efficiency of transport to the brain in
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healthy animals than the values reported for a published PAMAM G4- hydroxyl-terminated
dendrimer (Nance et al. 2016). Assessing a critical analysis of these results, the fact that G3-
DSA penetrated an intact BBB in healthy animals represents a crucial point. Indeed, most of
already published studies usually evaluate transport efficiency for in vivo disease models in
neurological disorders, when BBB is highly impaired. An overestimation of the actual crossing
ability of the used nanosystem has to be expected due to increased BBB permeability in
pathological conditions, if transport is not determined also in healthy animals. For G3-DSA,
demonstrating high transport efficiency across BBB in healthy animals, a higher transport rate,
if the BBB is affected by the neurological disorders or in brain cancer can be awaited.
Additionally, the concentration of G3-DSA reaching the brain falls in a range comparable to
the needed brain concentration for therapeutic molecules like nucleic acids. For example,
Tyler and colleagues demonstrated a decrease in gene expression of neurotensin receptor
using peptide nucleic acids at a brain molecular concentration almost 5-fold lower than G3-
DSA (Tyler et al. 1999). Nance et al. found a % ID of 0.003% (healthy animal) for G4-OH PAMAM
dendrimer loaded with N-acetylcysteine to efficiently deliver the drug load in the diseased
animal with 100-fold greater brain accumulation compared to free drug (Nance et al. 2017).
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Figure 39. Schematic representation of possible G3-DSA trafficking from the blood
to brain target cells in vivo. G3-DSA migrate from bloodstream to brain endothelial
cells. Astrocytes endfeet might take up G3-DSA and transfer it to neurons.
84
Although the target organ of this study is the brain, further experiments were performed to
study the biodistribution in several organs in mice. DSA uptake was observable in every
investigated organ, but mainly in kidney and liver (Figure 23).
According with previous publications high uptake in kidney is predictable for NPs with a size
of 5 nm as in the case of G3-DSA. The other main feature of DSA is to be positive-charged.
Positive-charges trigger high uptake in liver (Blanco et al., 2015). Moreover, the data suggest
some further considerations. The kidney is involved in two relevant processes: filtration and
reabsorption of blood molecules. In the glomerular all molecules of low molecular weight (<
60 KDa) are filtered out of the blood. For instance, most drugs are filtered from blood in the
glomerular; however, the overall renal excretion is controlled by what happens in the
tubules. More than 90 % of the filtrate is reabsorbed and finally the normal urine output is
just a small volume of what it is filtered at the beginning (Julian et al. 2009). The reabsorption
is the process that moves solutes and water out of the filtrate and back into the bloodstream
and this process could play an important role for DSA bioavailability. On one hand, high kidney
uptake of DSA indicates the activation of filtering mechanisms pulling the clearance of the
nanocompounds; on the other hand, that might prove the involvement of reabsorpative
processes designed to make DSA available again in bloodstream with the possibility to
increase the acting life of the nanocompound. WB on blood samples collected after 24 h of
G3-DSA treatment revealed a circulation of DSA and, therefore, NPs were still available for
uptake (Figure 24). Concurrently, these findings might support the hypothesis that G3-DSA is
partly reabsorbed by kidney tubules back into the bloodstream.
The biodistribution data showing high uptake of G3-DSA in off-target organs are due to the
fact that the nanosystem presented here has not been designed to selectively target the brain.
To improve specific targeting, functionalization with brain-directed molecules (eg.: antibodies,
receptor binding proteins) is necessary and possible due to the high flexibility and simple
functionalization possibilities of the DSA system.
Finally, the effect of G3-DSA on BBB integrity in vivo was evaluated by an Evans Blue assay.
The obtained results did not show increase in BBB permeability for G3-DSA-treated mice
compared to sham animals (Figure 25). Thus, a correlation between in vivo G3-DSA uptake
and BBB disruption could be excluded proving the biocompatibility of the investigated protein
nanocarrier also in vivo.
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In summary, combining in vitro and in vivo approaches by using BBB models, NVU cell cultures
as well as in vivo experiments on mice, it was demonstrated that DSA (I) are taken up by
neurovascular unit cells, (II) are transported from the bloodstream to the brain via
transcytosis, (III) are biocompatible for NVU cells, and (IV) do not impair BBB integrity.
The scientific questions addressed in this study defined a promising system to cross the BBB.
Thinking to future prospects, a new scientific question strongly emerges: is it possible to
efficiently load a drug cargo on DSA reaching the brain after systemic administration still
keeping effective the biological function of the loaded molecule?
Answering to this question will require further experiments but previously published studies
raise the hope of successful results. Indeed, Ng and colleagues demonstrated that DSA
functionalized with tumor suppressor p53 and cytochrome C as cargo increased uptake
specificity and impaired cell viability with activation of caspase 3 and 7 in cancer cells (Ng et
al. 2013). In this study the loading process of drugs on DSA did not affect the biological activity
of potential cargo.
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5.2 Fluorescent Nanodiamonds might contribute to the improvement of
nanotheranostics approaches for neurological diseases treatments
In the second part of this thesis dcHSA-fNDs as a novel theranostics tool for treatment of
neurological diseases via crossing an intact BBB were introduced. NDs have gained a strong
interest due to their unique optical and physicochemical properties responsible of their
potential intrinsic stable fluorescence, sophisticated surface and biocompatibility which could
enable personalized treatment by real time monitoring of drug delivery. Indeed, NDs fall in
the category of promising nanotheranostics tool, a combination of diagnosis and therapeutics
aiming to the transition from conventional medicine to personalized patient care (Jeelani et
al. 2014, Kim et al. 2013). The possibility to monitor the drug reaching a sufficient
concentration in the target and a maximum tolerable concentration in off-target organs would
give a significant advantage over current techniques, with separated treatment and
monitoring.  dcHSA-fNDs provided by Weina Liu and Marco Raabe from the lab of Prof. Dr.
Tanja Weil at the Max Planck Institute for polymer research in Mainz are composed of NDs
encapsulated by a programmable cationized HSA-based biopolymer providing a platform with
excellent colloidal stability and reproducible surface functionalization as previously described
by Wu and colleagues (Wu et al. 2015).
Aiming to study the potential transport of dcHSA-fNDs across the BBB, at first, the investigated
NPs need to penetrate a manolayer of brain endothelial cells.
Indeed, dcHSA-fNDs uptake was observable in bEnd.3 cells (brain endothelial cell lines) (Figure
26). The HSA-based biopolymer is produced by denaturation, cationization and PEGylation of
HSA. The presence of positive charges, which enabled the dcHSA-fNDs coating, also provides
a favorable condition for cell penetration due to electrostatic interaction with the negative
charges of the cell membrane as already described for DSA. Additionally, previous findings
have shown the peculiarity of serum albumin to trigger targeted cellular delivery for cancer or
rheumatoid arthritis (Wunder et al. 2003) also confirmed for nanosystems employing cationic
albumin (Abbasi et al. 2012, Lu et al. 2006) and that could be also a leading process for dcHSA-
fNDs uptake. Co-uptake studies aiming to investigate the underlying mechanism of uptake
using makers for specific endocytosis pathway demonstrated that the observed uptake
occurred via clathrin-mediated and caveolae-mediated endocytosis (Figure 28). Previous
findings have stated that often albumin is internalized by cells in general via receptor
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mediated endocytosis and specifically also via clathrin-mediated or caveolae-mediated uptake
(Schwegler et al. 1991, Yumoto et al. 2006). Therefore, due to the HSA-based coating of
dcHSA-fNDs we could expect one of this two mentioned uptake mechanisms. Additionally,
quantitative data suggest that dcHSA-fNDs follow a pathway, which starts preferentially with
caveolae-mediated uptake (70 %), which is the most common endocytosis in brain endothelial
cells (Hillaireau and Couvreur 2009, Frank et al. 2003) and it is also the endocytosis
mechanisms observed for albumin in pulmonary endothelial cells (Li et al. 2013, Schubert et
al. 2001).  dcHSA-fNDs uptake was additionally observed in primary murine astrocytes and
neurons suggesting also the possibility of delivery into target neuronal cells after crossing the
BBB (Figure 32).
These data suggest that dcHSA-fNDs could underlie a caveolae-mediated transcytosis
potentially leading to BBB crossing. Therefore, in vitro BBB transport was evaluated using a
monolayer of bEnd.3 cells sedeed on transwell inserts.
The transport data showed the ability of dcHSA-fNDs of different sizes (40 and 60 nm) to be
transported from one side to the other of the transwell system. Additionally, the suggested
transcytosis was happening in a size-independent manner (Figure 29). One limiting step for
nanocarriers to be transported could be the size, which may affect the ability of being
transported. Therefore, demonstrating that the size of the nanosystem does not affect the
transport rate suggests a higher flexibility in dcHSA-fNDs size and many possibilities of cargo
choice applied in drug delivery in future. Indeed, the additional loading of a therapeutic
molecule on nanoparticles, more than the physicochemical properties, affect the size with the
disadvantage of further modifying the biological “behavior” of the cargo-carrier system.
In order to understand the molecular mechanism leading to the transport, the intracellular
trafficking was studied by analysis of the colocalization of dcHSA-fNDs with endosomal
markers.  15 % of dcHSA-fNDs have been found in late endosomes after 24 h incubation in
bEnd.3 cells while only 2,5 % in early endosomes (Figure 30). This data are in agreement with
a previously published study of Wu and colleagues that already demonstrated the
LE/lysosomes localization of dcHSA-fNDs in cancer cells. They also demonstrated that cancer
cells treated with doxorubicin-loaded-dcHSA-fNDs were showing additionally release of
doxorubicin in the cell cytsosol underlying endosome/lysosome escape mechanisms (Wu et
al. 2015). However, although part of detectable dcHSA-fNDs localize in LE/lysosomes and their
88
fate is unpredictable since they might undergo trough several degradation or modifying
processes, transport data revealed that partly dcHSA-fNDs are able to avoid entrapment in
intracellular compartments and follow a transcytotic pathway responsible of their migration
from luminal to abluminal compartment.  Concerning the intracellular fate of dcHSA-fNDs
another possibility would have been the induction of autophagy with subsequent
internalization of dcHSA-fNDs in autophagosomes. dcHSA-fNDs colocalized with a percentage
of 0.98 ± 0.52 % with autophagosome that represents a negligible value considering the high
rate of basal autophagy in endothelial cells (Urbanek et al. 2014) (Figure 31).
Uptake and intracellular trafficking data revealed additionally a distal localization of dcHSA-
fNDs, which enabled the identification of dcHSA-fNDs located in actin bridges connecting two
adjacent cells in bEnd.3 (Figure 33) and primary neurons/glia co-culture (Figure 34).  The actin
bridges have been identified as tunneling nanotubes (TNT), membranous bridges connecting
cells over long distances and transferring various cellular components from cell to cell,
observed in many cell types in vitro and in developing embryos of different species in vivo
(Gerdes et al. 2013). Live cell imaging and time-lapse experiments in brain endothelial cells
clearly showed a unidirectional migration from an initiating cell to a target cell and a faster
movement while getting closer to the target cell (Figure 33; white arrows) maybe due to the
size of the dcHSA-fNDs-containing vesicles determining a slower speed of migration compared
to other previously published studies. Indeed, molecules migration along TNTs has been
shown to usually fall at least in the speed range of actin-dependent transport (Sun et al. 2012,
Gerdes et al. 2013). It seems that dcHSA-fNDs-vesicles need to overcome sort of bottle-neck
during the TNTs entry phase assumable from the observed shorter migration of dcHSA-fNDs-
vesicles close to the starting edge of the TNT (Figure 33). The data presented here confirm the
findings of Epperla and colleagues demonstrating trafficking via TNTs of bovine serum
albumin-coated-fNDs in HEK293T and SH-SY5Y cells in vitro (Epperla et al. 2015). These results,
in the context of transport across the BBB acquire an emerging interesting value: dcHSA-fNDs
might be potentially able to cross the BBB also migrating from one cell to the other without
need of being released in the extracellular environment.
The high biocompatibility of NDs among the many carbonaceous nanomaterials has been
strongly discussed over time. Although NDs showed no effects on cell viability in many cell
89
types, toxicity represents a parameter to evaluate very deeply in studies addressing
biomedical applications. Indeed, the biocompatibility has to be strictly evaluated according to
the specific cell types and the specific complex nanosystem. In this case the dcHSA-coating on
fNDs might trigger undesired and unpredictable interactions with components in biological
environment leading to possible deleterious effects in particular while working on primary
neuronal cells extremely sensitive to changes in their biological environment. Additionally, in
the case of brain delivery studies using transwell in vitro model, the BBB integrity represents
a parameter to monitor in order to exclude induced BBB disruption.
The biocompatibility data presented in this doctoral work showed that, dcHSa-fNDs do not
affect the viability of NVU cells and do not show impairment of BBB in vitro (Figure 36). The
observed general decrease of TEER values from time = 0 h until time = 10 h is predictable due
to perturbation in the system related to medium exchange. Indeed, the treatment at time = 0
produced a fluctuation-dependent instability in the TEER measurement that recovered within
the following hours.
The absence of cytotoxicity or BBB impairment raises the hope of a high biocompatibility.
However, further toxicity parameters need to be assessed in vivo. Indeed, clearance
mechanism remain still a very crucial aspect to be investigated due to the question whether
carbonaceous nanomaterials like fNDs are able to fulfill their proper function and, after, be
eliminated of the organism without long-term side effects.
The in vitro studies highlighted the potential of dcHSA-fNDs to cross the BBB. Thus, to assess
a possible clinical application, the ability of intravenously injected dcHSA-fNDs to reach the
brain via crossing an intact BBB in healthy animals was evaluated. dcHSA-fNDs have been
found in brain parenchyma and partly colocalizing with astrocytes and neurons (Figure 38).
This data clearly confirmed the ability of dcHSA-fNDs to cross the BBB, reach the brain
parenchyma and target different NVU cells in vivo. Combined with the previously discussed in
vitro data, it is possible to assume a transcytosis process involving also direct cell-cell
migration from brain endothelial cells to neurons via astrocytes incorporation occurring in vivo
as in vitro.
In summary, in the second part of this doctoral work, in vitro approaches based on cell culture,
transwell assay and confocal microscopy as well as in vivo studies have been used in order to
address the question whether dcHSA-fNDs are able to cross the BBB and reach the brain
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envisioning possible future neurological personalized treatment. It was demonstrated that
dcHSA-fNDs (I) are efficiently transported from one side of a BBB model to the other in a size-
independent manner, (II) are delivered to the abluminal side via intracellular trafficking and
direct cell-cell interactions mediated by TNTs, (III) are taken up by astrocytes and neurons and
(IV) are not toxic for endothelial and neuronal cells and do not impair BBB integrity.
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6. Conclusions and future prospects
Nanoparticle research is a fascinating branch of science founded in the observation of unusual,
often unexpected effects related to the tiny size of the particles. Indeed, as a matter of fact,
one of the most interesting aspects of nanoparticle research is that well-known materials like
titania, carbon, gold, diamond (to mention only a few) exhibit surprisingly different properties
on the nanoscale. This characteristic led to the development of a broad range of applications
involving materials at nanoscale. Nanomaterials started to be explored also in biomedicine
brought about an increasing number of findings demonstrating the great potential of
nanomedicine in treatment of many diseases. In application for neurological disorders the
broad range of nanoparticle properties led to the investigation of their possible use as
molecular Trojan horse to cross the BBB, an unassailable biological barrier hindering the
delivery of therapeutics to the brain after systemically administration.
This thesis provides evidence that dendrimer protein bioconjugates (DSA) as well as
fluorescent nanodiamonds coated with a human serum albumin based biopolymer (dcHSA-
fNDs) represent two potential nanosystems able to cross the BBB and move forward the field
of neurological disease treatments. Indeed, in this study it was demonstrated that DSA and
dcHSA-fNDs 1) are taken up by NVU cells, 2) transported from luminal to abluminal in vitro
and in vivo after intravenous injection, 3) do not affect cell viability and BBB integrity.
Looking at DSA, the streptavidin adapter offers a robust scaffold to the simple attachment of
biotinylated molecules. This characteristic provides high flexibility due to the simplicity of the
biotinylation process. Indeed, the bio-click systems have gained increasing interest since it is
ideally possible to imagine a therapy where a vial A with streptavidin adapter could be mixed
with a vial B containing any biotinylated drug and PAMAM dendrimers to provide a mixture
solution to inject driven by self-assembly mechanism. Like this, potentially any drugs could be
easily applied via DSA.  The protein nature of dendrimer protein bioconjugates exhibits an
additional intrinsic advantage: high biocompatibility due to the fact that protein based NPs
hold the ability to interact with biological systems and to be degraded, improving the
clearance of the compound.
For neurological disorders treatments, the use of DSA to transport endogenous molecules or
growth factors to complement endogenous mechanism for neuronal protection and repair
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might be envisioned. The observed high uptake into astrocytes could have potential for
treating reactive gliosis occurring in Alzheimer`s disease, multiple sclerosis and glioblastoma
by loading DSA with growth factors, such as NGF (nerve growth factor) which has been already
shown to be anti-gliosis and neuroprotective (Colangelo et al. 2014). Nonetheless, brain
targeted chemotherapeutics may also represent a possible suitable drug cargo for brain
tumor. Additionally, DSA could serve as a platform for gene therapy approaches. The
lysosomal escape mechanism associated to the cationic nature of DSA points to the possible
delivery of nucleic acids, which could compensate gene mutations often related to
neurological disorders. In case of prion diseases, a group of fatal neurodegenerative disorders
in human and animals (Prusiner 1998), PAMAM dendrimers with high surface density of amino
groups have been shown to be effective in inhibiting prion proteins, whose accumulation in
CNS is associated to neurological dysfunction (Supattapone et al. 1999, Lim et al. 2010). Thus,
the possibility of implementing DSA for treatment of prion diseases could be envisioned.
Furthermore, DSA provide the potential to combine anti-prion properties of dendrimers with
biotinylated therapeutic molecules in one delivery system.
On the other hand, talking about dcHSA-fNDs, the key feature of fNDs is the intrinsic optical
and magnetic nature that suggests a promising potential use for nanotheranostics being able
to follow the steps of a therapeutic treatment raising the hope of a personalized therapy from
which DSA are still far away. Combining new data obtained on the evaluation of the BBB
crossing ability with already published data, the NDs formulation (dcHSA-fNDs) investigated
in this work revealed excellent nanotheranostic potential for neurological disorders therapy
still presenting a lack of actual therapeutic strategies. NDs have been shown to improve the
sensitivity of MRI thanks to their dynamic nuclear spin polarization and the presence of NV
centers which might lead to achieve individual care plans for patients, by monitoring target
and off-target drug delivery. Additionally, it is possible to envision the use of dcHSA-fNDs for
therapy of brain tumors. Indeed, already Matsumura and Maeda in the 1986 demonstrated
that an intravenously injected Evans blue-albumin complex accumulated in sarcoma 180
tumors of ddY Mice (Matsumura and Maeda 1986). The retention of albumin in tumors has
since then been observed in various experimental solid tumors (e.g., sarcoma, ovarian
carcinoma, Novikof hepatoma, etc.) using radiolabeled- or dye-complexed serum albumin
(Sinn et al. 1990). Furthermore, fNDs have been demonstrated to achieve phototermal
reactivity (Ryu et al. 2016). Combining tumor localization and phototermal properties of fNDs
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could be an interesting potential therapeutic approach for selective tumor ablation.
Therefore, the dcHSA-fNDs may lead to a charming nanotheranostics approach for brain
tumor via crossing BBB and selectively target tumor site due to the human serum albumin
coating. Thus, combining the inner properties of fNDs, the possibility of anticancer drug
functionalization and the natural albumin-mediated recruitment at the tumor site might be
an innovative biomedical strategy.
However, to prove the use of DSA and dcHSA-fNDs for further clinical applications of
neurological disorders, beside the investigated ability to cross an intact BBB, further studies
have to be carried out to evaluate the efficiency of a drug cargo loaded on the
nanocompounds to address its therapeutic functions. Additionally, in both cases to achieve an
optimal efficiency, the biodistribution in off-target organs need to be reduced. Thus, to further
improve DSA and dcHSA-fNDs, functionalization with BBB specific targeting molecules (eg.
lectins, transferrin, angiopep-2, antibodies) represent an essential future prospect.
Furthermore, in vivo potential toxicity need to be more carefully addressed by analysis on
proinflammatory cytokines distribution, clearance and long term NPs fate.
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